Skip to main content
International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
. 2026 Oct 27;27(21):9600. doi: 10.3390/ijms27219600

Divergent Reactions of Coumarin- and 7-Azacoumarin-3-Carboxylic Acids with Azomethine Ylides: Spirocyclization and Ring Expansion

Alexey V Trifonov 1,*, Nurbol O Appazov 2,*, Lyudmila K Kibardina 1, Almir S Gazizov 1, Alexandra D Voloshina 1, Anna P Luybina 1, Alexey B Dobrynin 1,3, Igor A Litvinov 1, Aiym E Tolegen 4, Alexander R Burilov 1, Michail A Pudovik 1, Rakhymzhan A Turmanov 2, Nurgali I Akylbekov 2, Igor V Alabugin 5, Elena A Chugunova 1
Editor: Antonio Rescifina
PMCID: PMC13762739  PMID: 43027849

Abstract

A series of new spiro-fused polycyclic systems has been synthesized via cascade reactions of 7-azacoumarin-3-carboxylic acid and coumarin-3-carboxylic acid derivatives with azomethine ylides generated in situ from L-proline or sarcosine and various carbonyl components (ninhydrin, aceanthrenequinone, isatin, and substituted isatins). For the conventional cycloaddition products (derived from isatin with L-proline or sarcosine), the cascade reactions contain a 1,3-dipolar cycloaddition with a decarboxylation step, affording a single detectable diastereomer in each case. For those products for which single-crystal X-ray structures were obtained, the crystals belong to centrosymmetric space groups, so the compounds are racemic. The reaction of 7-azacoumarin-3-carboxylic acids with the ylides derived from L-proline and ninhydrin or aceanthrenequinone provides the first example of a pyrrolidine-to-piperidine ring expansion (5→6); this transformation is currently demonstrated only for a limited set of substrates and should be regarded as a proof-of-concept rather than a general method. Transformation differs mechanistically from the conventional cycloaddition–decarboxylation; the proposed mechanism is presented as a working hypothesis. The effect of the solvent on the structure of the final products of reaction of 7-azacoumarin-3-carboxylic acid with ylides based on sarcosine and isatins is shown: in methanol, ring-opened esters are formed, whereas in acetonitrile the coumarin fragment is retained. The structures of all products were established by comprehensive NMR spectroscopy, IR, and mass spectrometry. Single-crystal X-ray diffraction was performed for representative compounds 6a, 10, 12a, 17a, and 20a. The synthesized compounds were evaluated for their in vitro cytotoxic activity against M-HeLa, HuTu80, and A549 tumour cell lines, as well as against the normal Wi-38 fibroblast line. For compounds 10 and 17d, the IC50 values against M-HeLa cells were numerically similar to those of the reference drug 5-fluorouracil, while compound 6b gave an IC50 against HuTu80 cells numerically similar to that of 5-fluorouracil. Compound 10 gave a numerically lower IC50 value than 5-fluorouracil against A549 lung carcinoma cells. These results should be regarded as a preliminary cell-viability screening rather than evidence of therapeutic potential; the spirocyclic scaffolds provide a starting point for further structure–activity investigation.

Keywords: azacoumarin; coumarin; 1,3-dipolar cycloaddition; cytotoxicity; anti-tumor; X-ray structure

1. Introduction

The development of new drugs and functional materials remains one of the most active frontiers in organic chemistry. Particularly attractive targets are compounds built around nitrogen-containing heterocycles such as pyrrolidine, pyrroline, and piperidine—core motifs of numerous natural alkaloids and pharmacologically active substances [1,2,3].

Coumarin (2H-chromen-2-one) and its aza-analogues are privileged structural motifs in medicinal chemistry, widely represented in natural products and pharmaceuticals (Figure 1). Well-known examples include the immunosuppressive agent Scoparone [4], the anticoagulants Warfarin [5] and Dicoumarol [6], the antibiotics Clorobiocin and Novobiocin [7], the choleretic drug Hymecromone [8], and the anti-HIV agent Calanolide A [9,10].

Figure 1.

Figure 1

Commercially available biologically active coumarins.

Coumarin derivatives exhibit a wide range of biological activities: anti-HIV [11,12], anticancer [13,14,15,16,17], antimicrobial [18,19], antioxidant [20,21,22], anti-Alzheimer [23,24], anti-tuberculosis [25,26], anti-platelet activity [27], COX inhibitors [28], anti-inflammatory [29,30], anti-asthmatic [31,32], anti-viral [33,34] and DNA gyrase inhibitors [35,36]. In addition, fluorescent dyes based on coumarin structures are used as fluorescent probes in various biological systems [37,38].

Coumarin-3-carboxylic acids have emerged as a versatile platform for the construction of polycyclic frameworks. Chithanna et al. exploited them to prepare 3,4-dihydropyridones and 2-piperidinones via reactions with enaminones [39]. Song et al. reported an organocatalytic Diels–Alder reaction of coumarin-3-carboxylic acids with aldehydes, where the carboxyl group both enhanced dienophile reactivity and enabled catalyst release, delivering products in high yield and enantioselectivity [40]. Shankar and Swamy demonstrated an oxidative (4 + 2) cyclization of coumarin/chromene-3-carboxylic acids with alkynes or propargyl alcohols using a Ru(II) catalyst, while Hayashi et al. described a rhodium-catalysed (4 + 2) annulation with alkynes via C4–H bond cleavage [41].

1,3-dipolar cycloaddition is widely used in organic synthesis and chemical biology [42,43]. These reactions are based on the interaction of two molecules: a dipole, which is represented by azomethine ylides formed in situ, and a dipolarophile, such as compounds containing a double or triple bond [44,45,46,47]. The α,β-unsaturated lactone system of coumarins makes them ideal dipolarophiles, opening a direct route to complex polycyclic scaffolds with potential biological activity.

Coumarin-3-carboxylic acids can participate in 1,3-dipolar cycloaddition reactions as the alkene component [48]. Diastereoselective cycloaddition of azomethine ylides, generated in situ from heterocyclic carbonyl compounds such as indenoquinoxaline and isatin, to coumarin derivatives gives access to spiro-fused polyheterocyclic scaffolds [49]. The carboxyl group at C3 plays a dual role: it activates the coumarin ring toward cycloaddition and serves as a handle for subsequent decarboxylative transformations, making C3-carboxylated coumarins particularly attractive substrates compared to their unsubstituted counterparts.

Only isolated examples of 1,3-dipolar cycloaddition involving coumarin-3-carboxylic acids have been reported. Liu et al. [50] described a decarboxylative, regioselective cascade cycloaddition of 3-aminooxindole-derived azomethine ylides with coumarin-3-carboxylic acids (Scheme 1A), producing spiro[oxindole-pyrrolidine-dihydrocoumarin] derivatives bearing four contiguous stereocenters, including a spiroquaternary centre, in up to 90% yield and 15:1 diastereoselectivity.

Scheme 1.

Scheme 1

Known synthesis, [50] (A), known synthesis, [51] (B), and reactivity of azacoumarins disclosed in this work (C).

Rajeswari, Kumari and Khurana reported a one-pot four-component cycloaddition using coumarin-3-carboxylic acid, N-propargylated isatin, L-proline or sarcosine, and aryl azides in the presence of Cu(I) in glacial acetic acid at 60 °C, affording 1,2,3-triazole-conjugated spirooxoindole-pyrrolizines [51] (Scheme 1B).

Together, these precedents establish coumarin-3-carboxylic acids as versatile dipolarophiles whose carboxyl group tunes reactivity and enables downstream decarboxylative ring-forming steps. In the present work, we investigated the reactions of 7-azacoumarin-3-carboxylic and coumarin-3-carboxylic acids, each bearing a reactive endocyclic double bond, with a panel of azomethine ylides derived from L-proline or sarcosine combined with ninhydrin, aceanthrenequinone, isatin, or substituted isatin derivatives (Scheme 1C). The choice of the carbonyl component was found to be critical in determining whether the reaction follows the conventional (3 + 2) cycloaddition–decarboxylation pathway or the ring-expansion pathway. The factors governing this divergence are discussed in Section 2.1. The resulting complex polycyclic frameworks, combining the well-established biological profile of coumarins with newly introduced heterocyclic fragments, are expected to exhibit interesting pharmacological properties.

2. Results and Discussion

2.1. Chemistry

We began by exploring 1,3-dipolar cycloaddition reactions of 7-azacoumarin-3-carboxylic acid, which carries a reactive endocyclic double bond, with a series of azomethine ylides—to the best of our knowledge, the first application of azacoumarins as dipolarophiles in such reactions. Starting materials 1a,b were prepared by our previously reported method [52].

Reaction of 7-azacoumarin-3-carboxylic acid 1a with the azomethine ylide generated in situ from L-proline 2 and ninhydrin 3 was performed in refluxing absolute ethanol. The solvent employed is standard for 1,3-dipolar cycloadditions of this type [53,54]. Compound 6a was initially obtained in 45% yield by adding 20% excess L-proline and ninhydrin in solid form to a boiling solution of acid 1a. To determine the most effective preparative protocol for the formation of 6a, we compared three protocols differing in the mode of reagent addition and the use of preformed azomethine ylide 4 (Table S1, Supplementary Material). Adding a warm ethanolic solution of L-proline and ninhydrin to a refluxing solution of 1a increased the yield from 45% to 59% compared to the addition of solid reagents. The use of preformed ylide 4 afforded the highest yield (67%). Based on these results, we identified the protocol giving the highest isolated yield for obtaining compound 6a as the addition of preformed ylide 4 to acid 1a, refluxing in absolute ethanol, followed by refluxing the reaction mixture for 1 h. Purity was confirmed by 1H NMR analysis of the crude mixture and filtrate, which showed only one set of product signals alongside minor unidentified by-product peaks. Conversion was essentially quantitative; the yield loss arose solely from the purification step. Compound 6a is a ring-expansion product (pyrrolidine-to-piperidine, 5 → 6), not the conventional (3 + 2) cycloadducts described later. The same product 6a (67% yield) was obtained using pre-formed azomethine ylide 4 (Scheme 2).

Scheme 2.

Scheme 2

Reaction of 7-azacoumarin-3-carboxylic acids 1a,b with L-proline 2 and ninhydrin 3/ or azomethine ylide 4. Conditions: EtOH (abs.), reflux, 1 h (6a); MeOH, reflux, 8 h (6b). Isolated yields: 6a, 45% (in situ, solid reagents), 59% (in situ, ethanolic solution) and 67% (preformed 4); 6b, 46% (preformed 4).

To further probe the scope of this cascade, the phosphate-substituted 7-azacoumarin-3-carboxylic acid derivative 1b was reacted with the pre-formed azomethine ylide 4. The reaction was carried out in methanol at reflux for 8 h, which differs from the conditions used for 6a (absolute ethanol, reflux, 1 h). Under these conditions, the spiro-fused product 6b was isolated in 46% yield (Scheme 2). The phosphate group at the 5-position of the azacoumarin core does not alter the course of the cascade; the product 6b is structurally analogous to 6a, as confirmed by 1H, 13C, and 31P NMR spectroscopy (Figures S8–S12, Supplementary Materials). The lower yield of 6b compared to 6a (46% vs. 67%) may be attributed to the increased steric bulk and electron-withdrawing nature of the phosphate substituent, which could affect the solubility of the substrate and the efficiency of the final rearrangement step. In addition, the use of methanol instead of ethanol was necessary to achieve complete conversion due to better solubility of the phosphate-containing substrate in the more polar protic solvent. These results demonstrate that the ring-expansion cascade is tolerant of a phosphate substituent on the azacoumarin core, although the reaction conditions require adjustment.

Single crystals of 6a suitable for X-ray diffraction were obtained, allowing unambiguous determination of the relative configuration (Figure 2, Figure S1, Tables S2 and S3, Supplementary Materials). The compound crystallizes in the monoclinic space group P21/n with two independent molecules in the asymmetric unit. In both molecules, the heterocycle adopts a half-chair conformation along the C13–C18 bond. The two independent molecules differ in configuration at C12: C12A is R and C12B is S.

Figure 2.

Figure 2

Molecular structure of compound 6a. Colour code: blue—nitrogen, red—oxygen, dark gray—carbon, light gray—hydrogen.

The complete assignment of signals in 1H and 13C spectra for compound 6a was accomplished by using the 2D NMR techniques (COSY, 1H-13C HSQC and 1H-13C HMBC). 2D NMR data for compound 6a are provided in the Supplementary Materials (Figures S45–S47).

A plausible mechanism for piperidine ring formation is outlined in Scheme 3.

Scheme 3.

Scheme 3

Scheme 3

Possible mechanisms for the cascade forming compounds 6a,b.

We speculated that the reaction begins with deprotonation of 7-azacoumarin-3-carboxylic acid to give the corresponding betaine A. Given that the structurally similar isonicotinic acid exists, at least partially, as a zwitterion [55,56], this assumption is reasonable. The next step is the electrophilic ipso-substitution of the carboxylate group by the stabilized [57,58] azomethine ylide 4, furnishing intermediate B. Mechanistically, this step may proceed via a stepwise decarboxylation–alkylation sequence or a concerted pathway, similar to the known ipso-nitration [59,60], ipso-arylation [61] and protodecarboxylation [62] of aromatic carboxylates. Although this would lead to high-energy aryl anionic intermediates, such processes are not impossible [63]. Thus, formed charge-separated intermediate B then isomerizes to the neutral enol C. Notably, the enol C may undergo subsequent isomerization to the corresponding keto form. However, given that the equilibrium mixture of many 2-substituted 1,3-indandione derivatives contains a considerable amount of the enol form [64,65] especially in protic solvents, its existence in the present case is plausible. Subsequent steps may involve the Stevens-type rearrangement, resulting in ring expansion and formation of product 6. Overall, the feasibility of this reaction pathway is determined by (a) deprotonation of the carboxylic acid, which facilitates its decarboxylation; (b) the presence of a persistent azomethine ylide in the reaction mixture; and (c) stabilization of the enol form of intermediate C, which enables the ring expansion. The proposed mechanism for the ring expansion is tentative and has not been experimentally demonstrated.

Alternatively, the formation of intermediate C may be rationalized by conjugate addition of the enolate to the electron-deficient double bond of the azacoumarin (Scheme 3B). The resulting enolate E may then react with a second molecule of ylide 4 to furnish intermediate G. Subsequent decarboxylation and β-elimination restore the double bond and regenerate ylide 4. Intermediate C then undergoes the transformations depicted in Scheme 3A to afford the final product.

A third, purely polar pathway, suggested by one of the reviewers, is shown in Scheme 3C. Here the cascade proceeds through conjugate addition, decarboxylative elimination, and C–N fragmentation followed by intramolecular re-closure (intermediates H–K), without the involvement of an ammonium ylide. For the pathways in Scheme 3A,B, a radical-pair 1,2-shift is not unreasonable, because both fragments would be strongly stabilized: a captodative α-amino radical flanked by the two indandione carbonyl groups, and a migrating carbon conjugated with the azacoumarin π-system. The open question for these pathways is the formation of a genuine ammonium ylide under protic conditions, which the pathway in Scheme 3C avoids. Distinguishing between these alternatives will require further mechanistic study.

To broaden the scope of this cascade, we examined the reaction of 1a with the ylide derived from L-proline 2 and aceanthrenequinone 7 in refluxing absolute ethanol. Compound 8 was isolated in 53% yield (Scheme 4). The NMR spectral data of 8 closely parallel those of 6a and are provided in the Supplementary Materials (Figures S8 and S9 for compound 6a and Figures S13 and S14 for compound 8). To confirm the structure of the obtained product 8, correlation 1D/2D NMR spectroscopy (provided in the Supplementary Materials, Figures S48–S50) was carried out.

Scheme 4.

Scheme 4

Reaction of azacoumarin-3-carboxylic acid 1a with L-proline 2 and aceanthrenequinone 7.

Switching the carbonyl component to isatin 9a gave a different outcome. The reaction of 1a with the L-proline/isatin ylide proceeded via a cascade (3 + 2) cycloaddition–decarboxylation sequence, but delivered spiro-fused compound 10 bearing four stereocenters as a single diastereomer (Scheme 5), as confirmed by X-ray analysis (Figure 3, Figure S2, Tables S2 and S3, Supplementary Materials) and the NMR spectral data. The 1H and 13C spectra for compound 10 are provided in the Supplementary Materials (Figures S15 and S16). Compound 10 crystallizes in the monoclinic space group P21/n. The five-membered heterocycle N16–C15–C7–C8–C17 adopts a C7-envelope conformation, with the N16–C15–C8–C17 fragment planar and C7 deviating by 0.475 Å. The six-membered ring O10–C6–C5–C7–C8–C9 adopts a twist-boat conformation, with C7 and C8 displaced to the same side at unequal distances. The configurations C7 R, C8 S, C15 R, C17 R refer to the arbitrarily selected enantiomer shown in Figure 3.

Scheme 5.

Scheme 5

Reaction of azacoumarin-3-carboxylic acid 1a with L-proline 2 and isatin 9a. Compound 10 was obtained as a single diastereomer (racemic).

Figure 3.

Figure 3

Molecular structure of compound 10. Colour code: blue–nitrogen, red—oxygen, dark gray—carbon, light gray—hydrogen.

The reaction of 1a with ylides derived from sarcosine 11 and isatins 9a–d is notable because the outcome proved to be solvent-dependent. When the reaction is carried out under reflux in methanol, the azacoumarin ring opens to give ring-opened esters 12a,b. To prevent the formation of an ether fragment, we carried out the reaction in an acetonitrile medium, spiro compounds 13a–d are formed (Scheme 6). The interconversion between the two forms was confirmed by dedicated experiments: heating 13a in methanol caused complete conversion to 12a, whereas 12a spontaneously cyclised back to 13a in DMSO-d6 at room temperature, reaching completion after seven days (partial conversion already evident after 6 h), as monitored by 1H NMR (1H NMR spectra of a solution of compound 12a recorded after standing for 6 h at room temperature in DMSO-d6 are provided in the Supplementary Materials, Figure S54). The structures of 12a,b and 13a–d were established by 1H and 13C NMR (provided in the Supplementary Materials, Figures S17–S28), IR spectroscopy, and MALDI-TOF mass spectrometry; the structure of 12a was additionally confirmed by X-ray crystallography (Figure 4, Figure S3, Tables S2 and S3, Supplementary Materials). Compound 12a crystallizes in the monoclinic space group P21/c; the five-membered heterocycle N1–C2–C3–C4–C5 adopts an N1-envelope conformation (N1 displaced by 0.624 Å, all other rings planar). The configurations C3 R, C4 S, C5 S refer to the arbitrarily selected enantiomer shown in Figure 4. All products 12a,b and 13a–d were obtained as single detectable diastereomers (isolated as racemates).

Scheme 6.

Scheme 6

Reaction of azacoumarin-3-carboxylic acid 1a with sarcosine 11 and isatins 9a–d. Isolated yields: 12a, 52%; 12b, 67%; 13a–d, 36–61%. All products were obtained as single detectable diastereomers (racemic).

Figure 4.

Figure 4

Molecular structure of compound 12a. Colour code: blue—nitrogen, red—oxygen, dark gray—carbon, light gray—hydrogen.

To confirm the structure of the obtained product 13a, correlation 1D/2D NMR spectroscopy (provided in the Supplementary Materials, Figures S51–S53) was performed.

In the next stage, we examined the reaction of coumarin-3-carboxylic acid 14, bearing a bulky vitamin-B6-derived furopyridine substituent at C6 (reported previously by us [66]), with azomethine ylides from L-proline 2 and isatins 9a–d. Unexpectedly, acid 14 did not undergo cycloaddition under these conditions (Scheme 7) and returned virtually quantitatively in unchanged form as precipitate. Thus, the issue is not the decomposition of the substrate, but rather its low reactivity under the given conditions.

Scheme 7.

Scheme 7

Reaction of coumarin-3-carboxylic acid 14 with L-proline 2 and isatins 9a–d.

As a comparison, we examined coumarin-3-carboxylic acids 16a,b, which lack the furopyridine fragment, to assess their reactivity under the same conditions. These compounds 16a,b are known in the literature and were obtained using a similar method to compound 1a (by reacting the corresponding resorcylic aldehyde with Meldrum’s acid in an aqueous medium [52]). They reacted smoothly with azomethine ylides from L-proline 2 and isatins 9a–d, mirroring the behavior of acid 1a and giving single detectable diastereomers of pyrrolidine-containing spiro compounds 17a–d and 18. Neither the presence of an electron-withdrawing substituent nor its absence at the 6-position of the aromatic ring affected the outcome. Reaction of 16a with L-proline 2 and aceanthrenequinone 7 gave product 19 without pyrrolidine ring expansion, in contrast to acid 1a (Scheme 8). Because 16a differs from 14 only by the absence of the furopyridine fragment, this comparison directly supports the conclusion that the furopyridine substituent is responsible for the lack of reactivity of 14. The additional experiment with 16b (R1 = Cl) showed that an electron-withdrawing substituent at C6 does not prevent the reaction, further confirming that the effect is specific to the presence of furopyridine group rather than to substitution at C6 in general. However, exactly how the furopyridine substituent in 14 influences the reactivity-whether through steric shielding, conformational restriction, or electronic effects-remains difficult to establish and requires further investigation.

Scheme 8.

Scheme 8

Reaction of coumarin-3-carboxylic acids 16a,b with L-proline 2 and isatins 9a–d/ or aceanthrenequinone 7. All products were obtained as single detectable diastereomers (racemic).

Primarily the structures of 17a--d,18,19 were established by 1H and 13C NMR (provided in the Supplementary Materials, Figures S29–S40). Additionally, the structure of 17a was confirmed by X-ray crystallography (Figure 5, Figure S4, Tables S2 and S3, Supplementary Materials). The compound crystallizes as a DMSO solvate in the monoclinic space group P21/n. Both five-membered heterocycles—N5–C4–C3–C7–C6 and N5–C4–C26–C27–C23—adopt half-chair conformations along the C7–C6 and C27–C23 bonds, respectively. The configurations C3 S, C4 R, C6 R, C7 S refer to the arbitrarily selected enantiomer shown in Figure 5.

Figure 5.

Figure 5

Molecular structure of compound 17a. Colour code: blue—nitrogen, red—oxygen, dark gray—carbon, light gray—hydrogen.

Reaction of 16a with sarcosine-derived ylides from isatins 9a,b similarly furnished single detectable diastereomers of compounds 20a,b in 81% and 64% yield, respectively (Scheme 9). The 1H and 13C spectra for compound 20a,b are provided in the Supplementary Materials (Figures S41–S44). X-ray analysis of 20a (Figure 6, Figure S5, Tables S2 and S3, Supplementary Materials) confirmed crystallization in the monoclinic space group P21/n with 1 molecule of water as solvent; the five-membered heterocycle N5–C4–C3–C7–C6 adopts a half-chair along the C6–N5 bond. The configurations C3 R, C4 R, C7 R refer to the arbitrarily selected enantiomer shown in Figure 6.

Scheme 9.

Scheme 9

Reaction of coumarin-3-carboxylic acid 16a with sarcosine 11 and isatins 9a,b. Both products were obtained as single detectable diastereomers (racemic).

Figure 6.

Figure 6

Molecular structure of compound 20a. Colour code: blue—nitrogen, red—oxygen, dark gray—carbon, light gray—hydrogen.

For all conventional cycloaddition products (10, 12a,b, 13a–d, 17a–d, 18, 19, 20a,b), the X-ray structures (where available) reveal a consistent pattern: the newly formed stereocenters adopt a single relative configuration, which is rationalized by a concerted (3 + 2) cycloaddition via an endo-transition state. In this transition state, the dipole approaches the dipolarophile from the less hindered face, with the carbonyl group of the isatin moiety oriented endo relative to the coumarin/azacoumarin framework. This rationale is in full agreement with literature precedents for related azomethine ylide cycloadditions [49,50,51]. For the ring-expansion products 6a,b and 8, the stereochemical assignment is based solely on the X-ray structure of 6a; the analogous stereochemical relationships in 6b and 8 are assumed by analogy, as their NMR data are consistent with the same relative configuration.

The formation of ring-expansion products 6a,b and 8 is mechanistically distinct from the conventional (3 + 2) cycloadducts obtained with isatin-derived ylides. While the latter proceed via a concerted cycloaddition–decarboxylation sequence, the ring expansion involves a more complex pathway that likely proceeds through a stepwise decarboxylative substitution, tautomerization, and Stevens-type rearrangement.

It is important to emphasize that the ring-expansion transformation is currently demonstrated only for a limited set of substrates—specifically, 7-azacoumarin-3-carboxylic acid (1a,b) in combination with the ylides derived from L-proline and either ninhydrin or aceanthrenequinone. It should therefore be regarded as a proof-of-concept rather than a general method. The factors that determine whether the reaction follows the conventional cycloaddition pathway or the ring-expansion pathway appear to be governed primarily by the nature of the carbonyl component, although the heterocyclic core also contributes: the aceanthrenequinone-derived ylide gives the ring-expanded product 8 with 7-azacoumarin-3-carboxylic acid 1a, but the conventional cycloadduct 19 with coumarin-3-carboxylic acid 16a. Specifically, ninhydrin and aceanthrenequinone are stronger electrophiles and more rigid carbonyl components than isatin. Their vicinal tricarbonyl and quinone motifs, respectively, stabilize the enol form of the intermediate C (Scheme 3), which is a prerequisite for the Stevens-type rearrangement and subsequent ring expansion. In contrast, isatin and its substituted derivatives possess an amide NH group capable of participating in hydrogen bonding, and their less electrophilic carbonyl group directs the reaction toward the conventional (3 + 2) cycloaddition–decarboxylation pathway. The ring expansion also requires the presence of a persistent azomethine ylide in the reaction mixture and the stabilization of the enol form of intermediate C in the protic solvent used (absolute ethanol). Steric factors also play a role: the more compact and rigid structures of ninhydrin and aceanthrenequinone may favor the conformational arrangement required for the rearrangement, whereas the more flexible isatin-derived intermediates preferentially undergo the concerted cycloaddition.

Further systematic variation in the carbonyl component would be required to establish the generality of the ring-expansion transformation. At present, the limited substrate scope precludes any claim of broad applicability. The proposed mechanism for the ring expansion is tentative and has not been experimentally demonstrated; it is presented as a working hypothesis.

2.2. Preliminary Cell-Viability Screening

With a library of spiro-fused polycyclic compounds in hand, we evaluated their preliminary cytotoxic activity against the normal human fibroblast line Wi-38 and three tumor cell lines—M-HeLa, HuTu80, and A549—at concentrations of 1–100 μM using the MTT assay (Table 1).

Table 1.

Cytotoxic effects of synthesized polycyclic compounds on cancer and normal human cell lines 1,2.

Compounds IC50 (μM)
Cancer Cell Lines Normal Cell Line
M-HeLa HuTu80 A549 Wi-38
6a >100 >100 - 59.2 ± 3.7
6b >100 60.3 ± 5.8 >100 >100
8 >100 >100 >100 98.1 ± 1.2
10 59.2 ± 5.6 >100 84.7 ± 2.0 >100
13a >100 >100 >100 >100
13b >100 >100 >100 >100
13c >100 >100 90 ± 9.8 >100
13d >100 >100 >100 >100
17a >100 >100 >100 >100
17b >100 >100 >100 >100
17c 87.0 ± 7.3 >100 >100 >100
17d 66.9 ± 3.2 98.8 ± 10 99.6 ± 3.9 95.1 ± 1.5
18 >100 >100 >100 >100
19 >100 >100 >100 >100
20a >100 >100 >100 >100
20b >100 >100 >100 >100
5-fluorouracil 62.0 ± 4.7 65.2 ± 5.4 >100 61.9 ± 6.3
doxorubicin 3.5 ± 0.2 3.2 ± 0.2 2.0 ± 0.2 2.7 ± 0.2

1 Three independent experiments were carried out. 2 Compounds 12a,b were not included in the cytotoxicity screening because, in DMSO solution, they convert to compounds 13a,b, which precludes testing the pure ester forms.

Among the compounds tested, 10 and 17d showed IC50 values against M-HeLa cells numerically similar to those of 5-fluorouracil (IC50 59.2 ± 5.6 and 66.9 ± 3.2 μM, respectively, vs. 62.0 ± 4.7μM for the reference drug). Compound 6b showed moderate activity against HuTu80 cells (IC50 60.3 ± 5.8μM) and showed no measurable cytotoxicity toward the normal Wi-38 line at the highest concentration tested. Compound 10 gave a numerically lower IC50 value than 5-fluorouracil against A549 lung carcinoma cells (84.7 ± 2.0 vs. >100 μM); both values are in the high-micromolar range, and no formal statistical comparison between compounds was performed. For comparison, the widely used anticancer agent doxorubicin, included in Table 1 as an additional reference, exhibited IC50 values of 3.5 ± 0.2 μM against M-HeLa, 3.2 ± 0.2 μM against HuTu80 cells, 2.0 ± 0.2 μM against A549 cells, and 2.7 ± 0.2 μM against the normal Wi-38 line, confirming its potent but non-selective cytotoxicity. The newly synthesized compounds are considerably less active than doxorubicin. Compound 10 was less cytotoxic to the normal Wi-38 line than to M-HeLa cells under these conditions, but no formal statistical comparison was made and the difference is small relative to the experimental uncertainty; it should therefore be treated as a preliminary observation rather than as evidence of a favourable safety margin. The cell lines used here constitute a standard panel for initial cytotoxicity testing and were not selected for sensitivity to coumarin derivatives. Confirmation in an orthogonal viability assay and in cell lines relevant to coumarin pharmacology would be required before any therapeutic potential could be inferred.

3. Materials and Methods

3.1. Chemicals

3.1.1. General Methods

1H and 13C NMR spectra were recorded on a Bruker Avance 400 (Bruker, Billerica, MA, USA) spectrometer (at the frequencies of 400.05, 100.61 MHz, respectively), Bruker Avance III 500 (Bruker Corporation, Rheinstetten, Germany) spectrometer (at the frequencies of 500, 126 MHz, respectively) and on a Bruker Avance 600 spectrometer (at the frequencies of 600.1, 150.9 MHz, respectively and 242.94 MHz for 31P NMR). Values of the chemical shifts for the 1H and 13C nuclei are reported relative to the residual signals of the solvent (DMSO-d6). IR spectra were recorded in KBr pellets on a Bruker 3/5 E2_76513 Tensor-27 spectrometer in the range of 400–3600 cm–1. Mass spectra were recorded on an Ultraflex III TOF/TOF Bruker instrument (p-nitroaniline as the matrix) and an AmaZon X Bruker instrument. Elemental analysis was performed using a Carlo Erba EA 1108 (Carlo Erba, Cornaredo, Italy) instrument.

3.1.2. Single-Crystal X-Ray Diffraction

Data sets for the single crystals 6a, 10, 12a, 17a and 20a were collected on a Bruker SMART APEX CCD area detector using MoKα (0.71073 Å) radiation at a temperature of 110 K for 6a, 150 K for 10 and 12a, 105 K for 17a and 293(2) K for 20a. Data collection and indexing, determination, and refinement of unit cell parameters were carried out using the APEX4 software package (Bruker AXS, Madison, WI, USA). Numerical absorption correction based on the crystal shape, additional spherical absorption correction, and systematic error correction were performed using the SADABS software [67]. Using Olex2 [68], the structures were solved by the intrinsic phasing approach using SHELXT [69] and refined by the full-matrix least squares on F2 using SHELXL [70]. Nonhydrogen atoms were refined anisotropically. The positions of hydrogen atoms of methyl groups were found using rotating group refinement with idealized tetrahedral angles. The positions of the H(O) hydrogen atoms were found from Fourier maps, and these atoms were refined isotropically. The other hydrogen atoms were inserted at the calculated positions and refined as riding atoms. Images of the crystal structures were obtained using the software program Mercury [71]. Some reflections were omitted to improve the quality of the structure. In the crystal of compound 17a, one of the DMSO solvent molecules is disordered over two positions with an occupancy ratio of 0.72 to 0.28. High R-factor values arise due to the crystal’s weak reflective capabilities. Structure 17a contains a solvent-accessible volume of 519 Å3; we applied a solvent mask to calculate the position of an undefined solvent. The crystallographic data for structures 6a, 10, 12a, 17a and 20a reported in this article have been deposited with the Cambridge Crystallographic Data Center and are freely available on request on the website www.ccdc.cam.ac.uk/structures/ (accessed on 19 October 2026). The crystallographic data for structures 6a, 10, 12a, 17a and 20a are listed in Tables S2 and S3.

3.1.3. Procedures for the Synthesis of Compounds

2-(3,4-dihydro-2H-pyrrol-1-ium-1-yl)-1-oxo-1H-inden-3-olate 4

A mixture of L-proline 2 (0.35 g, 3.0 mmol) and ninhydrin 3 (0.53 g, 3.0 mmol) in absolute ethanol (5 mL) was placed in a 25-mL round-bottom flask equipped with a reflux condenser. The reaction mixture was heated under reflux for 1 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute ethanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford the azomethine ylide 4 (0.52 g, 81%) as a yellow solid. The product was sufficiently pure for subsequent transformations and was used without further purification. M.p. 215–218 °C; IR (KBr), ν, cm−1: 520, 722, 791, 893, 970, 1039, 1076, 1152, 1215, 1292, 1364, 1408, 1442, 1578, 1623, 1662, 1709, 3090, 3449. 1H NMR (400 MHz, DMSO-d6), δ ppm: 2.13 (2H, p, J = 7.9 Hz, CH2); 3.03 (2H, tq, J = 7.8, 2.5 Hz, CH2), 4.72 (2H, td, J = 7.8, 2.2 Hz, CH2), 7.36 (2H, dd, J = 5.2, 3.1 Hz, Ph), 7.46 (2H, dd, J = 5.2, 3.0 Hz, Ph), 9.13 (1H, s, CH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 19.02, 33.52, 59.06, 119.70, 132.02, 137.41, 155.78, 182.29. Found, %: C 73.34; H 5.11; N 6.59. C13H11NO2. Calculated, %: C 73.23; H 5.20; N 6.57.

3′-(5-(hydroxymethyl)-8-methyl-2-oxo-2H-pyrano [2,3-c]pyridin-3-yl)spiro[indene-2,2′-piperidine]-1,3-dione 6a

  • (1)

    A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.28 mmol) and absolute ethanol (5 mL). The mixture was heated to reflux with stirring, whereupon L-proline 2 (0.18 g, 1.53 mmol, 20 mol% excess) and ninhydrin 3 (0.27 g, 1.53 mmol, 20 mol% excess) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the solvent was removed under reduced pressure. The product 0.23 g (45%) was isolated by recrystallization of the residue from absolute ethanol (3 mL).

  • (2)

    A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.27 mmol) and absolute ethanol (3 mL). The mixture was heated to reflux with stirring. Separately, a warm solution of L-proline 2 (0.18 g, 1.53 mmol) and ninhydrin 3 (0.27 g, 1.53 mmol) in absolute ethanol (2 mL) was prepared and added dropwise to the boiling reaction mixture. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute ethanol (2 × 3 mL) and diethyl ether (2 × 3 mL), and dried in vacuo to afford compound 6a (0.30 g, 59%) as a brown solid.

  • (3)

    A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.27 mmol) and absolute ethanol (5 mL). The mixture was heated to reflux with stirring, and pre-formed azomethine ylide 4 (0.27 g, 1.27 mmol) was added in one portion. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the precipitate that formed was filtered off and discarded. The filtrate was concentrated under reduced pressure, and the residue was recrystallized from absolute ethanol (3 mL) to afford compound 6a (0.34 g, 67%) as a brown solid.

M.p. 228–230 °C; IR (KBr), ν, cm−1: 699, 721, 753, 782, 874, 896, 936, 1005, 1032, 1048, 1063, 1076, 1091, 1142, 1184, 1251, 1268, 1338, 1417, 1439, 1594, 1706, 1724, 1744, 2874, 2946, 3162, 3293, 3431.1H NMR (400 MHz, DMSO-d6), δ ppm: 1.65–1.72 (1H, m, CH), 1.84 (2H, d, J = 11.4 Hz, CH2), 2.33–2.42 (4H, m, CH3 + CH), 2.91 (1H, d, J = 12.6 Hz, CH), 3.28–3.31 (1H, m, CH), 3.48 (1H, dd, J = 12.6, 3.2 Hz, CH), 4.49–4.57 (2H, m, CH2OH), 5.39 (1H, t, J = 5.1 Hz, CH2OH), 7.78–7.81 (5H, m, Ph + CHarom), 8.17 (1H, S, CH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 18.65; 25.87; 26.19; 40.79; 40.99; 58.49; 66.33; 121.87; 123.25; 123.71; 130.60; 133.05; 135.88; 136.73; 136.09; 140.12; 141.20; 142.84; 146.10; 146.17; 159.22 199.50. MS (ESI-TOF), m/z: 405.1 [M + H]+. Found, %: C 68.37; H 5.06; N 7.02. C23H20N2O5. Calculated, %: C 68.31; H 4.98; N 6.93.

(3-(1,3-dioxo-1,3-dihydrospiro[indene-2,2′-piperidin]-3′-yl)-8-methyl-2-oxo-2H-pyrano [2,3-c]pyridin-5-yl)methyl dihydrogen phosphate 6b

A 25-mL round-bottom flask equipped with a reflux condenser was charged with phosphate-substituted 7-azacoumarin-3-carboxylic acid 1b (0.24 g, 0.762 mmol) and absolute methanol (5 mL). The mixture was heated to reflux with stirring, and pre-formed azomethine ylide 4 (0.16 g, 0.762 mmol) was added in one portion. The reaction mixture was refluxed with stirring for 8 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute methanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford compound 6b (0.17 g, 46%) as a brown solid. Subsequent purification of the product was not required. M.p. > 300 °C; IR (KBr), ν, cm−1: 496, 555, 611, 716, 780, 826, 928, 1049,1083, 1147, 1210, 1255, 1375, 1419, 1440, 1595, 1616, 1736, 2930, 3431. 1H NMR (600 MHz, DMSO-d6), δ ppm: 1.78–1.93 (3H, m, CH), 2.35 (3H, s, CH3), 2.43 (1H, qd, J = 12.6, 12.2, 2.8 Hz, CH), 3.11 (1H, d, J = 11.9 Hz, CH), 3.49 (1H, d, J = 12.0 Hz, CH), 3.53–3.56 (1H, m, CH), 4.96 (2H, q, J = 9.4, 6.3 Hz, CH2OH), 7.75–7.86 (5H, m, Ph + CHarom), 8.22 (1H, s, CH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 18.20; 23.75; 24.50; 40.55; 40.64; 60.97; 65.79; 121.39; 123.14; 123.35; 126.30; 131.98; 135.77; 136.45; 136.93; 139.34; 140.81; 143.41; 145.52; 146.67; 158.52; 197.10; 198.21. 31P NMR (243 MHz, DMSO-d6), δ, ppm: -0.7. MS (MALDI-TOF), m/z: 485.1 [M + H]+. Found, %: C 56.96; H 4.40; N 5.51; P 6.34. C23H21N2O8P. Calculated, %: C 57.03; H 4.37; N 5.78; P 6.39.

5-(hydroxymethyl)-8-methyl-3-(1-oxo-1H-spiro[aceanthrylene-2,2′-piperidin]-3′-yl)-2H-pyrano [2,3-c]pyridin-2-one 8

A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.15 g, 0.638 mmol) and absolute ethanol (2.5 mL). The mixture was heated to reflux with stirring, and L-proline 2 (0.08 g, 0.696 mmol) and aceanthrenequinone 7 (0.16 g, 0.696 mmol) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute ethanol (2 × 3 mL) and diethyl ether (2 × 3 mL), and dried in vacuo to afford compound 8 (0.16 g, 53%) as a black solid. The product was sufficiently pure and was used without further purification. M.p. 239–240 °C. IR(KBr), ν, cm−1: 491, 506, 530, 572, 624, 686, 748, 759, 776, 813, 857, 912, 983, 1017, 1033, 1089, 1103, 1139, 1175, 1190, 1121, 1266, 1284, 1337, 1362, 1422, 1460, 1576, 1596, 1624, 1701, 1725, 2863, 2935, 3263, 3288. 1H NMR (600 MHz, DMSO-d6), δ ppm: 1.83–1.89 (1H, m, CH), 2.00 (2H, d, J = 12.7 Hz, CH), 2.14 (3H, s, CH3), 2.44 (1H, dd, J = 24.9, 12.3 Hz, CH), 2.71 (1H, br. s, CH), 3.12 (1H, d, J = 13.5 Hz, CH), 3.74 (1H, dd, J = 13.1, 3.2 Hz, CH), 4.03–4.09 (2H, m, CH2OH), 5.15 (1H, t, J = 5.6 Hz, CH2OH), 7.12 (1H, s, Ph), 7.36 (1 H, t, J = 7.7 Hz, Ph), 7.74 (1H, t, J = 7.7 Hz, Ph), 7.79 (1H, t, J = 7.7 Hz, Ph), 7.96 (1 H, s, CHarom), 8.04 (1 H, d, J = 8.6 Hz, Ph), 8.18 (1 H, d, J = 8.5 Hz, Ph), 8.23 (1 H, d, J = 6.7 Hz, Ph), 8.79 (1H, s, CH), 8.89 (1 H, d, J = 8.6 Hz, Ph). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 18.43, 26.70, 27.39, 41.99, 42.33, 57.94, 69.77, 121.23, 123.55, 124.11, 124.47, 125.61, 127.05, 127.65, 128.12, 128.28, 129.98, 130.08, 130.15, 133.10, 133.49, 133.62, 139.65, 142.21, 143.28, 145.61, 145.68, 159.29, 202.86. MS (MALDI-TOF), m/z: 477.2 [M + H]+. Found, %: C 75.51; H 5.16; N 6.00. C30H24N2O4. Calculated, %: C 75.62; H 5.08; N 5.88.

1′-(hydroxymethyl)-4′-methyl-6a′,6b′,7′,8′,9′,11a′-hexahydro-6′H-spiro[indoline-3,11′-pyrido [4′,3′:5,6]pyrano [3,4-a]pyrrolizine]-2,6′-dione 10

A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.277 mmol) and absolute ethanol (5 mL). The mixture was heated to reflux with stirring, and L-proline 2 (0.18 g, 1.530 mmol) and isatin 9a (0.23 g, 1.530 mmol) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was recrystallized from DMF (5 mL) to afford compound 10 (0.31 g, 61%) as a white solid. M.p. 211–213 °C. IR(KBr), ν, cm−1: 558, 592, 614, 667, 701, 742, 759, 1011, 1047, 1020, 1203, 1238, 1266, 1340, 1385, 1443, 1475, 1598, 1621, 1715, 1737, 2927, 2954, 3450. 1H NMR (600 MHz, DMSO-d6), δ ppm: 1.65–1.70 (1H, m, CH2), 1.77–1.84 (1H, m, CH2), 1.90–1.94 (1H, m, CH2), 2.32 (1H, dd, J = 18.9, 7.4 Hz, CH), 2.37 (3H, s, CH3), 2.68 (1H, t, J = 8.0 Hz, CH), 3.11 (1H, dd, J = 14.4, 4.8 Hz, CH), 3.15–3.22 (1H, m, CH), 3.38 (1H, d, J = 10.4 Hz, CH), 4.02 (1H, dd, J = 13.0, 4.5 Hz, CH2OH), 4.35 (1H, t, J = 7.8 Hz, CH), 4.39 (1H, d, J = 10.8 Hz, CH2OH), 5.04 (1H, br.s, CH2OH), 6.70 (1H, d, J =7.7 Hz, Ph), 7.09 (1H, t, J = 7.5 Hz, Ph), 7.31 (1H, t, J = 7.8 Hz, Ph), 7.70 (1H, d, J = 7.5 Hz, Ph), 8.04 (1H, s, CHarom), 10.11 (1H, s, NH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 19.40, 26.53, 32.82, 41.05, 46.65, 50.79, 58.37, 67.99, 77.07, 110.32, 121.85, 123.87, 125.82, 128.41, 130.63, 134.98, 143.13, 143.45, 145.01, 146.12, 167.56, 177.57. MS (MALDI-TOF), m/z: 392.1 [M + H]+. Found, %: C 67.64; H 5.52; N 10.87. C22H21N3O4. Calculated, %: C 67.51; H 5.41; N 10.74.

Methyl 4′-(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)-1′-methyl-2-oxospiro[indoline-3,2′-pyrrolidine]-3′-carboxylate 12a

A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.277 mmol), sarcosine 11 (0.14 g, 1.573 mmol), isatin 9a (0.23 g, 1.573 mmol), and absolute methanol (3 mL). The reaction mixture was heated under reflux with stirring for 4 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute methanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford compound 12a (0.24 g, 52%) as a light green solid. The product was sufficiently pure and was used without further purification. M.p. 216 °C. IR(KBr), ν, cm−1: 552, 598, 633, 670, 701, 746, 783, 894, 933, 965, 991, 1023, 1066, 1103, 1126, 1189, 1218, 1275, 1294, 1336, 1359, 1434, 1474, 1552, 1603, 1625, 1697, 1734, 2742, 2877, 2919, 2949, 3090. 1H NMR (600 MHz, DMSO-d6), δ ppm: 2.00 (3H, s, CH3), 2.30 (3H, s, CH3), 3.15 (3H, s, OCH3), 3.32 (1H, dd, J = 9.9, 7.7 Hz, CH2), 3.47 (1H, dd, J = 9.9, 7.6 Hz, CH2), 4.23 (1H, d, J = 12.1 Hz, CH), 4.43–4.51 (2H, m, CH2OH + CH), 4.63 (1H, dd, J = 12.6, 6.3 Hz, CH2OH), 5.10 (1H, dd, J = 6.2, 4.7 Hz, CH2OH), 6.89 (1H, dd, J = 7.7, 0.9 Hz, Ph), 7.07 (1H, t, J =7.5, 1.0 Hz, Ph), 7.29 (1H, td, J = 7.7, 1.2 Hz, Ph), 7.48 (1H, d, J = 7.4 Hz, Ph), 7.81 (1H, s, CHarom), 10.31 (1H, s, NH), 10.87 (1H, s, OH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 20.23, 34.18, 36.32, 51.57, 55.37, 56.39, 60.73, 73.25, 110.56, 122.84, 125.14, 129.34, 130.11, 130.35, 135.43, 139.28, 142.99, 147.57, 150.49, 169.64, 179.46. MS (MALDI-TOF), m/z: 398.1 [M + H]+. Found, %: C 63.60; H 5.94; N 10.49. C21H23N3O5. Calculated, %: C 63.47; H 5.83; N 10.57.

Methyl 4′-(3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)-1′,5-dimethyl-2-oxospiro[indoline-3,2′-pyrrolidine]-3′-carboxylate 12b

A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.277 mmol), sarcosine 11 (0.14 g, 1.573 mmol), 5-methylisatin 9b (0.25 g, 1.573 mmol), and absolute methanol (3 mL). The reaction mixture was heated under reflux with stirring for 4 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute methanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford compound 12b (0.35 g, 67%) as a light yellow solid. The product was sufficiently pure and was used without further purification. M.p. 200–203 °C. IR(KBr), ν, cm−1: 552, 598, 613, 677, 739, 771, 821, 898, 935, 991, 1025, 1075, 1114, 1153, 1196, 1220, 1288, 1336, 1353, 1435, 1495, 1627, 1698, 1733, 2750, 2868, 2919, 2950, 3139, 3433. 1H NMR (400 MHz, DMSO-d6), δ ppm: 2.00 (3H, s, CH3), 2.29 (3H, s, CH3), 2.30 (3H, s, CH3), 3.14 (3H, s, OCH3), 3.28–3.32 (1H, m, CH2), 3.48 (1H, dd, J = 9.7, 7.7 Hz, CH), 4.19 (1H, d, J = 12.1 Hz, CH), 4.44–4.51 (2H, m, CH2OH + CH), 4.62 (1H, dd, J = 12.6, 6.0 Hz, CH2OH), 5.06 (1H, dd, J = 6.1, 4.7 Hz, CH2OH), 6.78 (1H, d, J = 7.8 Hz, Ph), 7.09 (1H, d, J = 7.6 Hz, Ph), 7.32 (1H, d, J = 1.7 Hz, Ph), 7.81 (1H, s, CHarom), 10.28 (1H, s, NH), 10.74 (1H, s, OH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 20.21, 21.20, 34.19, 36.30, 51.52, 55.40, 56.31, 60.75, 73.34, 110.27, 125.75, 129.43, 130.29, 130.33, 131.83, 135.39, 139.28, 140.53, 147.58, 150.49, 169.63, 179.46. MS (MALDI-TOF), m/z: 412.1 [M + H]+. Found, %: C 64.41; H 6.30; N 10.17. C22H25N3O5. Calculated, %: C 64.22; H 6.12; N 10.21.

9′-(hydroxymethyl)-2′,6′-dimethyl-1′,2′,3a′,9b′-tetrahydro-4′H-spiro[indoline-3,3′-pyrrolo [3′,4′:4,5]pyrano [2,3-c]pyridine]-2,4′-dione 13a

A 25-mL round-bottom flask equipped with a reflux condenser was charged with 7-azacoumarin-3-carboxylic acid 1a (0.30 g, 1.277 mmol), sarcosine (0.12 g, 1.348 mmol), isatin 9a (0.22 g, 1.348 mmol), and acetonitrile (5 mL). The reaction mixture was heated under reflux with stirring for 10 h. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: hexane/acetone, 1:1) to afford compound 13a (0.28 g, 61%) as a light yellow solid. M.p. 145–148 °C. IR(KBr), ν, cm−1: 472, 491, 537, 619, 679, 753, 912, 961, 1017, 1082, 1109, 1178, 1203, 1281, 1330, 1357, 1405, 1471, 1621, 1715, 2850, 2945, 3395. 1H NMR (600 MHz, DMSO-d6), δ ppm: 1.99 (3H, s, CH3), 2.39 (3H, s, CH3), 3.17 (1H, t, J = 9.1 Hz, CH2), 3.70 (1H, t, J = 8.3 Hz, CH2), 4.09 (1H, d, J = 12.2 Hz, CH), 4.16 (1H, ddd, J = 12.2, 9.4, 7.8 Hz, CH), 4.52 (1H, dd, J = 13.5, 5.5 Hz, CH2OH), 4.63 (1H, dd, J = 13.5, 5.4 Hz, CH2OH), 5.36 (1H, t, J = 5.4 Hz, CH2OH), 6.83 (1H, d, J = 7.7 Hz, Ph), 7.06 (1H, td, J = 7.5, 1.0 Hz, Ph), 7.27 (1H, td, J =7.7, 1.1 Hz, Ph), 7.36 (1H, d, J = 7.3 Hz, Ph), 8.23 (1H, s, CHarom), 10.41 (1H, s, NH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 18.87, 30.63, 33.81, 33.92, 48.87, 58.66, 58.75, 74.77, 109.65, 122.15, 124.14, 127.40, 128.88, 129.46, 133.12, 143.24, 143.48, 144.33, 144.92, 165.44, 177.16. MS (MALDI-TOF), m/z: 366.2 [M + H]+. Found, %: C 65.59; H 5.11; N 11.47. C20H19N3O4. Calculated, %: C 65.74; H 5.24; N 11.50.

9′-(hydroxymethyl)-2′,5,6′-trimethyl-1′,2′,3a′,9b′-tetrahydro-4′H-spiro[indoline-3,3′-pyrrolo [3′,4′:4,5]pyrano [2,3-c]pyridine]-2,4′-dione 13b

Similar to the previous one, from 1a (0.30 g, 1.277 mmol), sarcosine 11 (0.12 g, 1.348 mmol) and 5-methylisatin 9b (0.22 g, 1.348 mmol). Light yellow solid, yield 0.25 g (52%). M.p. 170–173 °C. IR(KBr), ν, cm−1: 470, 539, 596, 627, 689, 749, 914, 946, 1016, 1082, 1196, 1282, 1330, 1405, 1445, 1473, 1495, 1627, 1709, 1760, 2852, 2922, 3256, 3388. 1H NMR (600 MHz, DMSO-d6), δ ppm: 1.99 (3H, s, CH3), 2.30 (3H, s, CH3), 2.39 (3H, s, CH3), 3.16 (1H, t, J = 9.1 Hz, CH2), 3.68 (1H, t, J = 8.3 Hz, CH2), 4.06 (1H, d, J = 12.2 Hz, CH), 4.15 (1H, ddd, J = 12.2, 9.5, 7.9 Hz, CH), 4.52 (1H, dd, J = 13.5, 5.4 Hz, CH2OH), 4.62 (1H, dd, J = 13.5, 5.4 Hz, CH2OH), 5.36 (1H, t, J = 5.4 Hz, CH2OH), 6.72 (1H, d, J =7.9 Hz, Ph), 7.07–7.08 (1H, m, Ph), 7.18 (1H, s, Ph), 8.23 (1H, s, CHarom), 10.31 (1H, s, NH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 18.86, 20.69, 30.63, 33.83, 33.96, 48.86, 58.71, 58.76, 74.86, 109.39, 124.73, 127.43, 128.93, 129.69, 131.00, 133.11, 140.78, 143.46, 144.34, 144.91, 165.43, 177.11. MS (MALDI-TOF), m/z: 380.0 [M + H]+. Found, %: C 66.54; H 5.70; N 11.13. C21H21N3O4. Calculated, %: C 66.48; H 5.58; N 11.08.

5-chloro-9′-(hydroxymethyl)-2′,6′-dimethyl-1′,2′,3a′,9b′-tetrahydro-4′H-spiro[indoline-3,3′-pyrrolo [3′,4′:4,5]pyrano [2,3-c]pyridine]-2,4′-dione 13c

Similar to the previous one, from 1a (0.30 g, 1.277 mmol), sarcosine 11 (0.12 g, 1.348 mmol) and 5-chloroisatin 9c (0.25 g, 1.348 mmol). Light yellow solid, yield 0.23 g (45%). M.p. 183–186 °C. IR(KBr), ν, cm−1: 470, 559, 628, 683, 706, 745, 793, 819, 890, 975, 1016, 1081, 1120, 1176, 1204, 1270, 1331, 1357, 1405, 1440, 1479, 1621, 1716, 2849, 2952, 3223. 1H NMR (600 MHz, DMSO-d6), δ ppm: 2.01 (3H, s, CH3), 2.39 (3H, s, CH3), 3.14–3.17 (1H, m, CH2); 3.69–3.72 (1H, m, CH2), 4.16–4.20 (2H, m, 2CH), 4.52 (1H, dd, J = 13.5, 5.4 Hz, CH2OH), 4.62 (1H, dd, J =13.5, 5.4 Hz, CH2OH), 5.37 (1H, t, J = 5.4 Hz, CH2OH), 6.86 (1H, d, J = 8.3 Hz, Ph), 7.33 (1H, dd, J = 8.3, 2.2 Hz, Ph), 7.46 (1H, d, J = 2.2 Hz, Ph), 8.24 (1H, s, CHarom), 10.58 (1H, s, NH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 18.87, 30.62, 33.72, 33.98, 48.87, 58.78, 74.84, 111.17, 124.50, 126.24, 127.26, 129.41, 131.01, 133.12, 142.12, 143.59, 144.29, 145.01, 165.44, 176.93. MS (MALDI-TOF), m/z: 401.1 [M + H]+. Found, %: C 60.17; H 4.68; Cl 8.81; N 10.47. C20H18ClN3O4. Calculated, %: C 60.08; H 4.54; Cl 8.87; N 10.51.

5-bromo-9′-(hydroxymethyl)-2′,6′-dimethyl-1′,2′,3a′,9b′-tetrahydro-4′H-spiro[indoline-3,3′-pyrrolo [3′,4′:4,5]pyrano [2,3-c]pyridine]-2,4′-dione 13d

Similar to the previous one, from 1a (0.30 g, 1.277 mmol), sarcosine 11 (0.12 g, 1.348 mmol) and 5-bromoisatin 9d (0.30 g, 1.348 mmol). Light yellow solid, yield 0.20 g (36%). M.p. 164–166 °C. IR(KBr), ν, cm−1: 471, 537, 626, 691, 748, 817, 888, 913, 972, 1017, 1081, 1121, 1175, 1203, 1331, 1358, 1405, 1438, 1473, 1618, 1717, 2851, 2926, 3245, 3395. 1H NMR (600 MHz, DMSO-d6), δ ppm: 2.01 (3H, s, CH3), 2.39 (3H, s, CH3), 3.15 (1H, t, J = 8.8 Hz, CH2), 3.69–3.72 (1H, m, CH2), 4.16–4.20 (2H, m, 2CH), 4.52 (1H, dd, J = 13.6, 5.3 Hz, CH2OH), 4.62 (1H, dd, J =13.6, 5.3 Hz, CH2OH), 5.36 (1H, t, J = 5.4 Hz, CH2OH), 6.81 (1H, d, J = 8.2 Hz, Ph), 7.46 (1H, ddd, J = 8.4, 2.2, 0.9 Hz, Ph), 7.57 (1H, d, J = 2.1 Hz, Ph), 8.24 (1H, s, CHarom), 10.58 (1H, s, NH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 18.86, 29.58, 33.74, 33.99, 48.90, 58.79, 58.81, 74.81, 111.69, 113.92, 127.24, 131.38, 132.24, 133.11, 142.54, 143.61, 144.29, 145.04, 165.45, 176.81. MS (MALDI-TOF), m/z: 445.0 [M + H]+. Found, %: C 54.21; H 4.13; N 9.51. C20H18BrN3O4. Calculated, %: C 54.07; H 4.08; N 9.46.

3-hydroxy-6a,6b,7,8,9,11a-hexahydro-6H-spiro[chromeno [3,4-a]pyrrolizine-11,3′-indoline]-2′,6-dione 17a

A 25-mL round-bottom flask equipped with a reflux condenser was charged with coumarin-3-carboxylic acid 16a (0.25 g, 1.214 mmol) and absolute ethanol (5 mL). The mixture was heated to reflux with stirring, and L-proline 2 (0.14 g, 1.217 mmol) and isatin 9a (0.18 g, 1.214 mmol) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute ethanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford compound 17a (0.36 g, 82%) as a grey solid. The product was sufficiently pure and was used without further purification. M.p. 237 °C. IR (KBr), ν, cm−1: 431, 451, 466, 500, 545, 557, 574, 616, 643, 665, 729, 756, 812, 826, 854, 909, 928, 980, 1025, 1048, 1120, 1157, 1181, 1207, 1299, 1358, 1461, 1511, 1620, 1702, 1757, 2416, 2664, 2690, 2811, 2877, 2979, 3059, 3128, 3367.1H NMR (400 MHz, DMSO-d6), δ ppm: 1.59–1.87 (3H, m, CH), 2.31 (1H, dt, J = 12.6, 7.6 Hz, CH), 2.58 (1H, t, J = 7.1 Hz, CH), 3.09–3.15 (1H, m, CH), 3.26 (1H, dd, J = 11.2, 3.3 Hz, CH), 3.97 (1H, d, J = 11.3 Hz, CH), 4.34 (1H, ddd, J = 8.1, 6.4, 3.2 Hz, CH), 6.06 (1H, d, J = 8.4 Hz, Ph), 6.17 (1H, dd, J = 8.4, 2.4 Hz, Ph), 6.31 (1H, d, J = 2.4 Hz, Ph), 6.70 (1H, d, J = 7.7 Hz, Ph), 7.07 (1H, t, J = 7.5 Hz, Ph), 7.27 (1H, t, J = 7.6 Hz, Ph), 7.67 (1H, d, J = 7.5 Hz, Ph), 9.58 (1H, s, OH), 10.00 (1H, s, NH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 27.01, 33.80, 43.00, 48.06, 51.30, 67.90, 77.15, 103.96, 108.89, 110.64, 112.00, 122.49, 127.34, 127.52, 128.97, 130.73, 144.38, 152.53, 158.55, 168.72, 178.67. MS (MALDI-TOF), m/z: 363.1 [M + H]+. Found, %: C 69.80; H 5.12; N 7.52. C21H18N2O4. Calculated, %: C 69.60; H 5.01; N 7.73.

3-hydroxy-5′-methyl-6a,6b,7,8,9,11a-hexahydro-6H-spiro[chromeno [3,4-a]pyrrolizine-11,3′-indoline]-2′,6-dione 17b

Similar to the previous one, from 16a (0.25 g, 1.214 mmol), L-proline 2 (0.14 g, 1.217 mmol) and 5-methylisatin 9b (0.195 g, 1.214 mmol). Grey solid, yield 0.38 g (83%). M.p. 238 °C. IR (KBr), ν, cm−1: 430, 445, 469, 505, 545, 564, 584, 601, 631, 666, 679, 705, 752, 820, 848, 926, 983, 1005, 1045, 1076, 1119, 1156, 1176, 1209, 1300, 1349, 1493, 1510, 1624, 1698, 1750, 2341, 2415, 2693, 2811, 2876, 2979, 3054, 3349. 1H NMR (400 MHz, DMSO-d6), δ ppm: 1.58–1.68 (1H, m, CH), 1.74–1.89 (2H, m, CH), 2.27–2.31 (1H, m, CH), 2.33 (3H, s, CH3), 2.58 (1H, t, J = 7.2 Hz, CH), 3.12 (1H, ddd, J = 10.7, 8.5, 5.1 Hz, CH), 3.25 (1H, dd, J = 11.2, 3.3 Hz, CH), 3.94 (1H, d, J = 11.3 Hz, CH), 4.33 (1H, ddd, J = 7.8, 6.4, 3.2 Hz, CH), 6.08 (1H, d, J = 8.4 Hz, Ph), 6.18 (1H, dd, J = 8.4, 2.4 Hz, Ph), 6.30 (1H, d, J = 2.4 Hz, Ph), 6.59 (1H, d, J = 7.9 Hz, Ph), 7.08 (1H, dd, J = 8.0, 1.6 Hz, Ph), 7.50 (1H, s, Ph), 9.56 (1H, s, OH), 9.88 (1H, s, NH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 21.89, 26.99, 33.80, 43.03, 48.04, 51.30, 67.91, 77.26, 103.92, 108.98, 110.32, 112.01, 127.41, 128.09, 129.02, 130.94, 131.31, 141.91, 152.50, 158.49, 168.74, 178.65. MS (MALDI-TOF), m/z: 377.1 [M + H]+. Found, %: C 70.15; H 5.40; N 7.41. C22H20N2O4. Calculated, %: C 70.20; H 5.36; N 7.44.

5′-chloro-3-hydroxy-6a,6b,7,8,9,11a-hexahydro-6H-spiro[chromeno [3,4-a]pyrrolizine-11,3′-indoline]-2′,6-dione 17c

Similar to the previous one, from 16a (0.21 g, 1.019 mmol), L-proline 2 (0.12 g, 1.043 mmol) and 5-chloroisatin 9c (0.19 g, 1.043 mmol). Light yellow solid, yield 0.27 g (52%). M.p. 239 °C. IR (KBr), ν, cm−1: 431, 454, 469, 505, 564, 626, 680, 714, 736, 820, 860, 927, 985, 1050, 1076, 1119, 1158, 1174, 1206, 1300, 1349, 1463, 1512, 1620, 1733, 1749, 2804, 2973, 3087, 3373. 1H NMR (500 MHz, DMSO-d6), δ ppm: 1.60–1.70 (1H, m, CH), 1.76–1.83 (1H, m, CH), 1.87–1.92 (1H, m, CH), 2.34 (1H, dt, J = 13.9, 7.9 Hz, CH), 2.60 (1H, t, J = 6.9 Hz, CH), 3.15 (1H, ddd, J = 10.4, 8.3, 5.4 Hz, CH), 3.29 (1H, dd, J = 11.2, 3.1 Hz, CH), 4.08 (1H, d, J = 6.9 Hz, CH), 4.36 (1H, td, J = 7.4, 3.1 Hz, CH), 6.16 (1H, d, J = 8.4 Hz, Ph), 6.26 (1H, dd, J = 8.4, 2.3 Hz, Ph), 6.35 (1H, d, J = 2.3 Hz, Ph), 6.74 (1H, d, J = 8.3 Hz, Ph), 7.36 (1H, dd, J = 8.3, 1.9 Hz, Ph), 7.85 (1H, d, J = 1.8 Hz, Ph), 9.62 (1H, s, OH), 10.18 (1H, s, NH). 13C NMR (126 MHz, DMSO-d6), δ, ppm: 27.04, 33.79, 42.95, 47.94, 51.22, 68.03, 77.34, 104.06, 108.65, 112.04, 112.18, 126.62, 127.73, 128.98, 129.38, 130.70, 143.32, 152.54, 158.66, 168.62, 178.42. MS (MALDI-TOF), m/z: 419.0 [M + Na]+. Found, %: C 63.37; H 4.37; Cl 8.87; N 6.98. C21H17N2O4Cl. Calculated, %: C 63.56; H 4.32; Cl 8.93, N 7.06.

5′-bromo-3-hydroxy-6a,6b,7,8,9,11a-hexahydro-6H-spiro[chromeno [3,4-a]pyrrolizine-11,3′-indoline]-2′,6-dione 17d

Similar to the previous one, from 16a (0.21 g, 1.019 mmol), L-proline 2 (0.12 g, 1.043 mmol) and 5-bromoisatin 9d (0.23 g, 1.043 mmol). Grey solid, yield 0.21 g (47%). M.p. 233 °C. IR (KBr), ν, cm−1: 505, 543, 582, 603, 624, 665, 679, 707, 757, 817, 862, 984, 1049, 1077, 1119, 1157, 1207, 1299, 1348 1463, 1511, 1620, 1703, 1750, 2972, 3042, 3087, 3373. 1H NMR (500 MHz, DMSO-d6), δ ppm: 1.61–1.69 (1H, m, CH), 1.76–1.83 (1H, m, CH), 1.86–1.93 (1H, m, CH), 2.34 (1H, dt, J = 13.9, 8.0 Hz, CH), 2.60 (1H, t, J = 6.6 Hz, CH), 3.15 (1H, br.s, CH), 3.27–3.30 (1H, m, CH), 4.09 (1H, d, J = 11.1 Hz, CH), 4.35 (1H, t, J = 8.5 Hz, CH), 6.16 (1H, d, J = 8.4 Hz, Ph), 6.26 (1H, d, J = 8.3 Hz, Ph), 6.34 (1H, s, Ph), 6.69 (1H, d, J = 8.2 Hz, Ph), 7.49 (1H, d, J = 8.3 Hz, Ph), 7.97 (1H, s, Ph), 9.62 (1H, s, OH), 10.19 (1H, s, NH). 13C NMR (126 MHz, DMSO-d6), δ, ppm: 27.02, 33.77, 42.94, 47.90, 51.21, 68.02, 77.29, 104.05, 108.65, 112.16, 112.54, 114.23, 128.94, 129.76, 130.39, 133.54, 143.71, 152.52, 158.64, 168.59, 178.29. MS (MALDI-TOF), m/z: 465.0 [M + Na]+. Found, %: C 57.16; H 4.02; N 6.17; Br 18.38. C21H17N2O4Br. Calculated, %: C 57.14; H 3.85; N 6.35; Br 18.14.

2-chloro-3-hydroxy-6a,6b,7,8,9,11a-hexahydro-6H-spiro[chromeno [3,4-a]pyrrolizine-11,3′-indoline]-2′,6-dione 18

A 25-mL round-bottom flask equipped with a reflux condenser was charged with 16b (0.11 g, 0.457 mmol), L-proline 2 (0.052 g, 0.457 mmol), isatin 9a (0.067 g, 0.457 mmol), and absolute ethanol (5 mL). The mixture was refluxed with stirring for 1 h. After cooling, the solvent was removed under reduced pressure, and the residue was recrystallized from ethanol (3 mL) to afford compound 18 (0.17 g, 94%) as a white solid. M.p. 175 °C. IR (KBr), ν, cm−1: 492, 572, 620, 652, 676, 757, 834, 884, 931, 1027, 1155, 1216, 1329, 1357, 1431, 1472, 1512, 1620, 1718, 2874, 2971, 3216.1H NMR (500 MHz, DMSO-d6), δ ppm: 1.62–1.68 (1H, m, CH), 1.77–1.83 (1H, m, CH), 1.86–1.90 (1H, m, CH), 2.31–2.37 (1H, m, CH), 2.61 (1H, t, J = 7.3 Hz, CH), 3.13 (1H, ddd, J = 10.7, 8.4, 5.1 Hz, CH), 3.30 (1H, dd, J = 11.2, 3.3 Hz, CH), 4.02 (1H, d, J = 11.3 Hz, CH), 4.36 (1H, ddd, J = 8.0, 6.5, 3.3 Hz, CH), 6.13 (1H, s, Ph), 6.55 (1H, s, Ph), 6.75 (1H, dd, J = 7.8, 1.0 Hz, Ph), 7.12 (1H, td, J = 7.6, 1.1 Hz, Ph), 7.33 (1H, td, J = 7.7, 1.2 Hz, Ph), 7.71 (1H, d, J = 7.4 Hz, Ph), 10.07 (1H, s, NH). 13C NMR (126 MHz, DMSO-d6), δ, ppm: 26.45, 33.22, 47.17, 50.74, 67.52, 76.69, 104.71, 109.91, 110.22, 114.83, 122.11, 126.43, 127.07, 128.20, 130.40, 143.80, 150.51, 153.42, 167.74, 177.99. MS (MALDI-TOF), m/z: 398.1 [M + H]+. Found, %: C 63.74; H 4.15; Cl 8.72; N 6.83. C21H17ClN2O4. Calculated, %: C 63.56; H 4.32; Cl 8.93; N 7.06.

3′-hydroxy-6a′,6b′,7′,8′,9′,11a′-hexahydro-1H,6′H-spiro[aceanthrylene-2,11′-chromeno [3,4-a]pyrrolizine]-1,6′-dione 19

A 25-mL round-bottom flask equipped with a reflux condenser was charged with coumarin-3-carboxylic acid 16a (0.25 g, 1.214 mmol) and absolute ethanol (5 mL). The mixture was heated to reflux with stirring, and L-proline 2 (0.14 g, 1.217 mmol) and aceanthrenequinone 7 (0.28 g, 1.217 mmol) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute ethanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford compound 19 (0.39 g, 71%) as a dark brown solid. The product was sufficiently pure and was used without further purification. M.p. 169 °C. IR (KBr), ν, cm−1: 427, 457, 469, 485, 502, 526, 559, 617, 637, 666, 695, 712, 744, 775, 818, 853, 897, 927, 979, 1045, 1073, 1092, 1118, 1157, 1179, 1206, 1232, 1280, 1306, 1357, 1381, 1396, 1427, 1460, 1512, 1532, 1576. 1600, 1625, 1696, 1753, 1922, 2610, 2703, 2807, 2872, 2964, 3048. 1H NMR (400 MHz, DMSO-d6), δ ppm: 1.59–1.65 (1H, m, CH), 1.85–1.93 (2H, m, CH), 2.39 (1H, dt, J = 11.3, 7.6 Hz, CH), 2.50–2.52 (1H, m, CH), 3.21–3.26 (1H, m, CH), 3.44–3.47 (1H, m, CH), 4.31 (1H, br.s, CH), 4.36 (1H, d, J = 11.4 Hz, CH), 5.90 (1H, dd, J = 8.4, 2.4 Hz, Ph), 6.16 (1H, d, J = 8.4 Hz, Ph), 6.25 (1H, d, J = 2.4 Hz, Ph), 7.67 (2H, dt, J = 34.5, 7.7 Hz, Ph), 7.82 (1H, dd, J = 8.4, 7.0 Hz, Ph), 8.10 (1H, d, J = 6.7 Hz, Ph), 8.18 (1H, d, J = 8.7 Hz, Ph), 8.25 (1H, d, J = 8.5 Hz, Ph), 8.69 (1H, d, J = 8.5 Hz, Ph), 8.93 (1H, s, Ph), 9.39 (1H, s, OH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 26.58, 33.46, 41.68, 48.09, 51.64, 67.89, 80.01, 103.46, 108.47, 111.48, 123.52, 123.79, 124.29, 126.52, 127.10, 127.80, 128.27, 128.30, 130.11, 130.17, 133.32, 133.42, 136.54, 144.85, 151.91, 157.86, 168.39, 203.08. MS (MALDI-TOF), m/z: 448.1 [M + H]+. Found, %: C 77.98; H 4.85; N 3.24. C29H21NO4. Calculated, %: C 77.84; H 4.73; N 3.13.

7-hydroxy-2-methyl-1,2,3a,9b-tetrahydro-4H-spiro[chromeno [3,4-c]pyrrole-3,3′-indoline]-2′,4-dione 20a

A 25-mL round-bottom flask equipped with a reflux condenser was charged with coumarin-3-carboxylic acid 16a (0.25 g, 1.214 mmol) and absolute ethanol (5 mL). The mixture was heated to reflux with stirring, and sarcosine 11 (0.11 g, 1.236 mmol) and isatin 9a (0.18 g, 1.224 mmol) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the solvent was removed under reduced pressure. The solid residue was recrystallized from a mixture of ethanol and diethyl ether (1:1, 3 mL) to afford compound 20a (0.33 g, 81%) as a white solid. M.p. 252 °C. IR (KBr), ν, cm−1: 433, 460, 490, 514, 562, 606, 621, 648, 681, 716, 742, 753, 816, 869, 945, 969, 1017, 1109, 1169, 1212, 1264, 1326, 1361, 1384, 1444, 1469, 1522, 1597, 1620, 1719, 2508, 2623, 2703, 2803, 2867, 2945, 3063, 3410, 3511. 1H NMR (400 MHz, DMSO-d6), δ ppm: 1.97 (3H, s, CH3), 3.17 (1H, t, J = 8.8 Hz, CH), 3.55 (1H, t, J = 8.1 Hz, CH), 3.89 (1H, dt, J = 12.4, 8.4 Hz, CH), 4.05 (1H, d, J = 12.3 Hz, CH), 6.38 (1H, d, J = 2.4 Hz, CH), 6.60 (1H, dd, J = 8.3, 2.4 Hz, Ph), 6.81 (1H, d, J = 7.1 Hz, Ph), 7.04 (1H, td, J = 7.5, 1.0 Hz, Ph), 7.09 (1H, d, J = 8.4 Hz, Ph), 7.25 (1H, td, J = 7.7, 1.3 Hz, Ph), 7.33 (1H, d, J = 7.0 Hz, Ph), 10.37 (1H, s, NH). 13C NMR (101 MHz, DMSO-d6), δ, ppm: 35.02, 35.90, 50.06, 61.54, 75.86, 103.76, 110.52, 113.13, 113.23, 123.02 125.15, 129.95, 130.29, 130.35, 144.18, 150.81, 158.07, 167.39, 178.29. MS (MALDI-TOF), m/z: 359.0 [M + Na]+. Found, %: C 67.89; H 4.75; N 8.27. C19H16N2O4. Calculated, %: C 67.85; H 4.80; N 8.33.

7-hydroxy-2,5′-dimethyl-1,2,3a,9b-tetrahydro-4H-spiro[chromeno [3,4-c]pyrrole-3,3′-indoline]-2′,4-dione 20b

A 25-mL round-bottom flask equipped with a reflux condenser was charged with coumarin-3-carboxylic acid 16a (0.21 g, 1.019 mmol) and absolute ethanol (3 mL). The mixture was heated to reflux with stirring, and sarcosine 11 (0.095 g, 1.067 mmol) and 5-methylisatin 9b (0.168 g, 1.043 mmol) were added in one portion as solids. The reaction mixture was refluxed with stirring for 1 h. After cooling to room temperature, the precipitated solid was collected by vacuum filtration, washed with absolute ethanol (2 × 5 mL) and diethyl ether (2 × 5 mL), and dried in vacuo to afford compound 20b (0.23 g, 64%) as a white solid. The product was sufficiently pure and was used without further purification. M.p. 255 °C. IR (KBr), ν, cm−1: 431,457, 523, 563, 618, 662, 724, 818, 845, 961, 1014, 1082, 1112, 1168, 1188, 1232, 1254, 1331, 1438, 1454, 1472, 1495, 1517, 1588, 1629, 1722, 2957, 3032, 3335. 1H NMR (600 MHz, DMSO-d6), δ ppm: 1.97 (3H, s, CH3), 2.29 (3H, s, CH3), 3.16 (1H, t, J = 8.8 Hz, CH), 3.54 (1H, t, J = 8.1 Hz, CH), 3.87 (1H, dt, J = 12.4, 8.5 Hz, CH), 4.02 (1H, d, J = 12.3 Hz, CH), 6.37 (1H, d, J = 2.4 Hz, CH), 6.60 (1H, dd, J = 8.3, 2.4 Hz, Ph), 6.70 (1H, d, J = 7.8 Hz, Ph), 7.05 (1H, d, J = 7.8 Hz, Ph), 7.08 (1H, d, J = 8.4 Hz, Ph), 7.15 (1H, s, Ph), 9.66 (1H, br.s, OH), 10.25 (1H, s, NH). 13C NMR (151 MHz, DMSO-d6), δ, ppm: 21.21, 34.56, 35.41, 49.54, 61.09, 75.47, 103.26, 109.76, 112.69, 112.71, 125.24, 129.43, 129.88, 130.01, 131.34, 141.22, 150.31, 157.55, 166.85, 177.74. MS (MALDI-TOF), m/z: 351.0 [M + H]+. Found, %: C 68.32; H 5.09; N 7.87. C20H18N2O4. Calculated, %: C 68.56; H 5.18; N 8.00.

3.2. Biology

The purity of all final compounds was rigorously evaluated using a comprehensive set of physicochemical methods, namely: elemental analysis (C, H, N), MALDI-TOF mass spectrometry, and 1H and 13C NMR spectroscopy. The purity of the most biologically active compounds 6b, 10, and 17d was further confirmed by quantitative 1D 1H NMR (qNMR) spectroscopy and was found to be ≥97%. The data of qNMR experiments provided in the Supplementary Materials (Table S4).

3.2.1. Cell Lines and Materials

The following tumor cell cultures were used in the experiments: M-HeLa clone 11 (epithelioid cervical carcinoma, a subclone of HeLa designated M-HeLa); HuTu 80 (human duodenal adenocarcinoma); A 549 (human lung carcinoma) and the normal human embryonic lung fibroblast cell line Wi-38. All cell lines were obtained from the “Vertebrate Cell Culture Collection” of the General Research Center at the Institute of Cytology, Russian Academy of Sciences. Cells were cultured in Eagle’s MEM standard growth medium (EMEM) containing sodium pyruvate (without HEPES), supplied by Wuhan Servicebio Co., Ltd., Wuhan, China, and supplemented with 10% fetal bovine serum and 1% essential amino acids.

3.2.2. Cytotoxicity Assay

The cytotoxic effect on cells was assessed using a colorimetric cell proliferation assay (MTT test). Cells were seeded into 96-well Nunc plates at a density of 5 × 103 cells per well in 100 μL of culture medium and incubated in a CO2 incubator at 37 °C for 24 h. Following incubation, the culture medium was removed, and solutions of the test compounds, prepared directly in fresh nutrient medium, were added to the wells. To enhance solubility, DMSO was included at a final concentration not exceeding 1% in the experimental wells. Control samples (1% DMSO) were run in parallel with the experimental groups. Cell viability in these wells was 98–100%, indicating the correctness of the culture conditions and the reliability of the results obtained. To rule out compound interference with the MTT readout, compound-only controls (without cells) were included; no significant absorbance above background was observed. After 24 h of incubation with the compounds, the medium was aspirated, and 100 μL of serum-free medium containing MTT (0.5 mg/mL) was added to each well. The plates were then incubated for an additional 4 h at 37 °C. To dissolve the formazan crystals, 100 μL of DMSO was added to each well. Absorbance was measured at 540 nm using an Invitrologic microplate reader (Russia). All experiments were performed in triplicate for each compound. The IC50 values were determined by means of the online calculator MLA-Quest Graph™ IC50 Calculator (AAT Bioquest, Inc., Sunnyvale, CA, USA, 2026) https://www.aatbio.com/tools/ic50-calculator, accessed on 19 October 2026. Full dose–response curves are provided in the Supplementary Materials (Figures S55–S72). The fitting procedure used a four-parameter logistic (sigmoidal) dose–response model.

4. Conclusions

A series of new spiro-fused polycyclic compounds were prepared via cascade reactions of 7-azacoumarin-3-carboxylic acid and coumarin-3-carboxylic acid derivatives with azomethine ylides. For the conventional cycloaddition products (from 7-azacoumarin-3-carboxylic acid derivatives with sarcosine or L-proline and isatins; from coumarin-3-carboxylic acid derivatives with sarcosine or L-proline and isatins or aceanthrenequinone), the cascade reactions contain a 1,3-dipolar cycloaddition with a decarboxylation step, affording a single diastereomer in each case. Single-crystal X-ray diffraction was performed for the representative compounds 6a, 10, 12a, 17a, and 20a: these products crystallize in centrosymmetric space groups and are therefore racemic. The reaction of 7-azacoumarin-3-carboxylic acids with the ylides derived from L-proline and ninhydrin or aceanthrenequinone provides the first example of a pyrrolidine-to-piperidine ring expansion (5→6); this transformation is currently demonstrated only for a limited set of substrates and should be regarded as a proof-of-concept rather than a general method. The factors governing the divergence between the conventional cycloaddition and ring-expansion pathways appear to be determined primarily by the electrophilicity and rigidity of the carbonyl component, as well as by the ability of the intermediate to stabilize the enol form required for the Stevens-type rearrangement. Transformation differs mechanistically from the conventional cycloaddition–decarboxylation; the proposed mechanism is presented as a working hypothesis. All reactions of the conventional cycloaddition type proceeded with high diastereoselectivity, affording a single detectable diastereomer in each case irrespective of the number of stereocenters formed.

The cytotoxic activity of selected compounds was evaluated in vitro. For compounds 10 and 17d, the IC50 values against M-HeLa cells were numerically similar to that of the reference drug 5-fluorouracil, while compound 6b gave an IC50 against HuTu80 cells numerically similar to that of 5-fluorouracil, and no measurable cytotoxicity toward the normal Wi-38 line at the highest concentration tested. Compound 10 gave a numerically lower IC50 value than 5-fluorouracil against A549 lung carcinoma cells, warranting further investigation within this series; however, these results should be interpreted as preliminary screening data and do not constitute evidence of therapeutic potential.

Acknowledgments

The authors are grateful to the Collective Spectral-Analytical Center of the Federal Research Center of the Kazan Scientific Center of RAS for technical support of the studies. X-ray studies were performed using the equipment of the Federal Research Center Kazan Scientific Center of RAS. Authors are grateful to S.V. Syakaev (Arbuzov Institute of Organic and Physical Chemistry) for providing the qNMR and 1D/2D NMR spectroscopy experiments.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms27219600/s1.

ijms-27-09600-s001.zip (5.7MB, zip)

Author Contributions

Synthesis—A.V.T., L.K.K., N.O.A., A.E.T., N.I.A. and R.A.T.; writing—review and editing—A.R.B., A.S.G. and I.V.A.; writing—original draft preparation, conceptualization—E.A.C.; biological studies—A.P.L.; biological studies supervision—A.D.V.; X-ray studies—A.B.D. and I.A.L.; project administration, supervision—A.R.B., M.A.P. and I.V.A. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are contained within the article or in Supplementary Materials or are available upon request from the corresponding author Alexey V. Trifonov.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Statement

Synthetic (synthesis of compounds 4, 10, 12a,b) work was funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (Grant No. AP23488720). https://korkyt.edu.kz/en/staticpages/476, accessed on 19 October 2026. Synthesis of compounds 6a,b, 8, 13a–d, 17a–d, 18, 19, 20a,b; X-ray and biological studies were conducted at the Arbuzov Institute of Organic and Physical Chemistry, and were funded by the government assignment for the FRC Kazan Scientific Center of RAS.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Robertson J., Stevens K. Pyrrolizidine Alkaloids. Nat. Prod. Rep. 2014;31:1721–1788. doi: 10.1039/C4NP00055B. [DOI] [PubMed] [Google Scholar]
  • 2.Döndas H., de Gracia Retamosa M., Sansano J. Current Trends towards the Synthesis of Bioactive Heterocycles and Natural Products Using 1,3-Dipolar Cycloadditions (1,3-DC) with Azomethine Ylides. Synthesis. 2017;49:2819–2851. doi: 10.1055/s-0036-1588423. [DOI] [Google Scholar]
  • 3.Padwa A. Use of Nitrogen and Oxygen Dipole Ylides for Alkaloid Synthesis. Arkivoc. 2018;2018:23–49. doi: 10.24820/ark.5550190.p010.416. [DOI] [Google Scholar]
  • 4.Hanh N.T., Van C.A., Son N.T. Recent Advances in Bioactive Coumarin Scoparone: A Comprehensive Review. Fitoterapia. 2026;188:106966. doi: 10.1016/j.fitote.2025.106966. [DOI] [PubMed] [Google Scholar]
  • 5.Xue L., Singla R.K., He S., Arrasate S., González-Díaz H., Miao L., Shen B. Warfarin–A Natural Anticoagulant: A Review of Research Trends for Precision Medication. Phytomedicine. 2024;128:155479. doi: 10.1016/j.phymed.2024.155479. [DOI] [PubMed] [Google Scholar]
  • 6.Yildirim M., Poyraz S., Ersatir M. Recent Advances on Biologically Active Coumarin-Based Hybrid Compounds. Med. Chem. Res. 2023;32:617–642. doi: 10.1007/s00044-023-03025-x. [DOI] [Google Scholar]
  • 7.Zeydi M.M., Kalantarian S.J., Kazeminejad Z. Overview on Developed Synthesis Procedures of Coumarin Heterocycles. J. Iran. Chem. Soc. 2020;17:3031–3094. doi: 10.1007/s13738-020-01984-1. [DOI] [Google Scholar]
  • 8.Plotnikova E.Y. Known and Unknown Hymecromone. A Review. Cons. Medicum. 2024;26:324–330. doi: 10.26442/20751753.2024.5.202877. [DOI] [Google Scholar]
  • 9.Brahmachari G., K Jash S. Naturally Occurring Calanolides: An Update on Their Anti-HIV Potential and Total Syntheses. Recent Pat. Biotechnol. 2014;8:3–16. doi: 10.2174/1872208307666131218123753. [DOI] [PubMed] [Google Scholar]
  • 10.Yu D., Suzuki M., Xie L., Morris-Natschke S.L., Lee K. Recent Progress in the Development of Coumarin Derivatives as Potent Anti-HIV Agents. Med. Res. Rev. 2003;23:322–345. doi: 10.1002/med.10034. [DOI] [PubMed] [Google Scholar]
  • 11.Liu Y.-P., Yan G., Xie Y.-T., Lin T.-C., Zhang W., Li J., Wu Y.-J., Zhou J.-Y., Fu Y.-H. Bioactive Prenylated Coumarins as Potential Anti-Inflammatory and Anti-HIV Agents from Clausena Lenis. Bioorg. Chem. 2020;97:103699. doi: 10.1016/j.bioorg.2020.103699. [DOI] [PubMed] [Google Scholar]
  • 12.Zhu M., Ma L., Wen J., Dong B., Wang Y., Wang Z., Zhou J., Zhang G., Wang J., Guo Y., et al. Rational Design and Structure− Activity Relationship of Coumarin Derivatives Effective on HIV-1 Protease and Partially on HIV-1 Reverse Transcriptase. Eur. J. Med. Chem. 2020;186:111900. doi: 10.1016/j.ejmech.2019.111900. [DOI] [PubMed] [Google Scholar]
  • 13.Ahmed E.Y., Latif N.A.A., El-Mansy M.F., Elserwy W.S., Abdelhafez O.M. VEGFR-2 Inhibiting Effect and Molecular Modeling of Newly Synthesized Coumarin Derivatives as Anti-Breast Cancer Agents. Bioorg. Med. Chem. 2020;28:115328. doi: 10.1016/j.bmc.2020.115328. [DOI] [PubMed] [Google Scholar]
  • 14.Sanduja M., Gupta J., Singh H., Pagare P.P., Rana A. Uracil-Coumarin Based Hybrid Molecules as Potent Anti-Cancer and Anti-Bacterial Agents. J. Saudi Chem. Soc. 2020;24:251–266. doi: 10.1016/j.jscs.2019.12.001. [DOI] [Google Scholar]
  • 15.Eker Y., Şenkuytu E., Ölçer Z., Yıldırım T., Çiftçi G.Y. Novel Coumarin Cyclotriphosphazene Derivatives: Synthesis, Characterization, DNA Binding Analysis with Automated Biosensor and Cytotoxicity. J. Mol. Struct. 2020;1209:127971. doi: 10.1016/j.molstruc.2020.127971. [DOI] [Google Scholar]
  • 16.Lin M.-H., Wang J.-S., Hsieh Y.-C., Zheng J.-H., Cho E.-C. NO2 Functionalized Coumarin Derivatives Suppress Cancer Progression and Facilitate Apoptotic Cell Death in KRAS Mutant Colon Cancer. Chem. Biol. Interact. 2019;309:108708. doi: 10.1016/j.cbi.2019.06.021. [DOI] [PubMed] [Google Scholar]
  • 17.Zhao J.-W., Wu Z.-H., Guo J.-W., Huang M.-J., You Y.-Z., Liu H.-M., Huang L.-H. Synthesis and Anti-Gastric Cancer Activity Evaluation of Novel Triazole Nucleobase Analogues Containing Steroidal/Coumarin/Quinoline Moieties. Eur. J. Med. Chem. 2019;181:111520. doi: 10.1016/j.ejmech.2019.07.023. [DOI] [PubMed] [Google Scholar]
  • 18.Koparde S., Hosamani K.M., Barretto D.A., Joshi S.D. Microwave Synthesis of Coumarin-Maltol Hybrids as Potent Antitumor and Anti-Microbial Drugs: An Approach to Molecular Docking and DNA Cleavage Studies. Chem. Data Collect. 2018;15:41–53. doi: 10.1016/j.cdc.2018.03.004. [DOI] [Google Scholar]
  • 19.Ostrowska K. Coumarin-Piperazine Derivatives as Biologically Active Compounds. Saudi Pharm. J. 2020;28:220–232. doi: 10.1016/j.jsps.2019.11.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mangasuli S.N., Hosamani K.M., Managutti P.B. Microwave Assisted Synthesis of Coumarin-Purine Derivatives: An Approach to in Vitro Anti-Oxidant, DNA Cleavage, Crystal Structure, DFT Studies and Hirshfeld Surface Analysis. Heliyon. 2019;5:e01131. doi: 10.1016/j.heliyon.2019.e01131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Suwito H., Rosydah N., Ramadhan R., Haq K.U. Synthesis, Structure Determination and Antioxidant Activity of Chalcone–Theiazole–Coumarine Hybrid Molecules. Rasayan J. Chem. 2025;18:1207–1217. doi: 10.31788/RJC.2025.1819162. [DOI] [Google Scholar]
  • 22.Koparir P. Bioactivity and Quantum Chemical Calculations of a New Coumarine Derivative as a Strong Antioxidant, Antimicrobial and Anti-Cancer Substance. Maced. J. Chem. Chem. Eng. 2023;42:1–12. doi: 10.20450/mjcce.2023.2554. [DOI] [Google Scholar]
  • 23.Verma V., Kumar N., Kumar S. Anti-Alzheimer Potential of Coumarin Derivatives: A Review. World J. Adv. Res. Rev. 2023;20:825–835. doi: 10.30574/wjarr.2023.20.1.2094. [DOI] [Google Scholar]
  • 24.Kamel N.N., Aly H.F., Fouad G.I., Abd El-Karim S.S., Anwar M.M., Syam Y.M., Elseginy S.A., Ahmed K.A., Booles H.F., Shalaby M.B., et al. Anti-Alzheimer Activity of New Coumarin-Based Derivatives Targeting Acetylcholinesterase Inhibition. RSC Adv. 2023;13:18496–18510. doi: 10.1039/d3ra02344c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Patil S.V., Shaikh M.M., Karpoomath R.V., Dhawale S.A. Exploring the Potential of Coumarin as a Potent Antitubercular Agent. Mini-Rev. Med. Chem. 2026;26:564–582. doi: 10.2174/0113895575407145251126055745. [DOI] [PubMed] [Google Scholar]
  • 26.Mujeeb S., Singh K., Yogi B., Ansari V., Sinha S. A Review on Coumarin Derivatives as Potent Anti-Tuberculosis Agents. Mini Rev. Med. Chem. 2022;22:1064–1080. doi: 10.2174/1389557521666210927124511. [DOI] [PubMed] [Google Scholar]
  • 27.Ramsis T.M., Ebrahim M.A., Fayed E.A. Synthetic Coumarin Derivatives with Anticoagulation and Antiplatelet Aggregation Inhibitory Effects. Med. Chem. Res. 2023;32:2269–2278. doi: 10.1007/s00044-023-03148-1. [DOI] [Google Scholar]
  • 28.Revankar H.M., Bukhari S.N.A., Kumar G.B., Qin H.-L. Coumarins Scaffolds as COX Inhibitors. Bioorg. Chem. 2017;71:146–159. doi: 10.1016/j.bioorg.2017.02.001. [DOI] [PubMed] [Google Scholar]
  • 29.Saadati F., Chahardehi A.M., Jamshidi N., Jamshidi N., Ghasemi D. Coumarin: A Natural Solution for Alleviating Inflammatory Disorders. Curr. Res. Pharmacol. Drug Discov. 2024;7:100202. doi: 10.1016/j.crphar.2024.100202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bansal Y., Sethi P., Bansal G. Coumarin: A Potential Nucleus for Anti-Inflammatory Molecules. Med. Chem. Res. 2013;22:3049–3060. doi: 10.1007/s00044-012-0321-6. [DOI] [Google Scholar]
  • 31.Wang J., Fu Y., Wei Z., He X., Shi M., Kou J., Zhou E., Liu W., Yang Z., Guo C. Anti-Asthmatic Activity of Osthole in an Ovalbumin-Induced Asthma Murine Model. Respir. Physiol. Neurobiol. 2017;239:64–69. doi: 10.1016/j.resp.2017.01.011. [DOI] [PubMed] [Google Scholar]
  • 32.Leal L.K.A.M., Silva A.H., de Barros Viana G.S. Justicia Pectoralis, a Coumarin Medicinal Plant Have Potential for the Development of Antiasthmatic Drugs? Rev. Bras. Farmacogn. 2017;27:794–802. doi: 10.1016/j.bjp.2017.09.005. [DOI] [Google Scholar]
  • 33.Hu Y., Chen W., Shen Y., Zhu B., Wang G.-X. Synthesis and Antiviral Activity of Coumarin Derivatives against Infectious Hematopoietic Necrosis Virus. Bioorg. Med. Chem. Lett. 2019;29:1749–1755. doi: 10.1016/j.bmcl.2019.05.019. [DOI] [PubMed] [Google Scholar]
  • 34.Mishra S., Pandey A., Manvati S. Coumarin: An Emerging Antiviral Agent. Heliyon. 2020;6:e03217. doi: 10.1016/j.heliyon.2020.e03217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Liu H., Xia D.-G., Chu Z.-W., Hu R., Cheng X., Lv X.-H. Novel Coumarin-Thiazolyl Ester Derivatives as Potential DNA Gyrase Inhibitors: Design, Synthesis, and Antibacterial Activity. Bioorg. Chem. 2020;100:103907. doi: 10.1016/j.bioorg.2020.103907. [DOI] [PubMed] [Google Scholar]
  • 36.Abo-Salem H.M., Ali E.A., El-Mowafi S.A., Abdel-Aziz M.S., El-Sawy E.R., Abd El Salam H.A. New Sulfonamide-Tethered Coumarin Derivatives as Potential DNA Gyrase Inhibitors: Design, Synthesis, Antimicrobial Evaluation, and in Silico Study. J. Mol. Struct. 2024;1296:136860. doi: 10.1016/j.molstruc.2023.136860. [DOI] [Google Scholar]
  • 37.Alizadeh A., Farajpour B., Mohammadi S.S., Sedghi M., Naderi-Manesh H., Janiak C., Knedel T. Design and Synthesis of Coumarin-Based Pyrazolopyridines as Biocompatible Fluorescence Dyes for Live-Cell Imaging. ChemistrySelect. 2020;5:9362–9369. doi: 10.1002/slct.202002289. [DOI] [Google Scholar]
  • 38.Aydıner B. A Chemodosimeter Approach for Selective Colorimetric and Fluorimetric Cyanide Detection Using Coumarin Based Fluorescent Dyes. J. Photochem. Photobiol. A Chem. 2019;382:111916. doi: 10.1016/j.jphotochem.2019.111916. [DOI] [Google Scholar]
  • 39.Chithanna S., Roy A., Yang D.-Y. Acid-Catalyzed, Regioselective [3 + 3] Annulation of Enaminones and α-Substituted Cinnamic Acids: Access to 3,4-Dihydropyridones and 2-Piperidinones. Org. Biomol. Chem. 2021;19:9897–9905. doi: 10.1039/D1OB01115D. [DOI] [PubMed] [Google Scholar]
  • 40.Song A., Zhang X., Song X., Chen X., Yu C., Huang H., Li H., Wang W. Construction of Chiral Bridged Tricyclic Benzopyrans: Enantioselective Catalytic Diels–Alder Reaction and a One-Pot Reduction/Acid-Catalyzed Stereoselective Cyclization. Angew. Chem. Int. Ed. 2014;53:4940–4944. doi: 10.1002/anie.201402170. [DOI] [PubMed] [Google Scholar]
  • 41.Hayashi M., Komori K., Usuki Y., Satoh T. Rhodium-Catalyzed Annulative Coupling of Coumarin-3-Carboxylic Acids with Alkynes. Chem. Lett. 2023;52:307–309. doi: 10.1246/cl.230082. [DOI] [Google Scholar]
  • 42.Harris T., Alabugin I.V. Strain and Stereoelectronics in Cycloalkyne Click Chemistry. Mendeleev Commun. 2019;29:237–248. doi: 10.1016/j.mencom.2019.05.001. [DOI] [Google Scholar]
  • 43.Shybanov D.E., Kukushkin M.E., Grishin Y.K., Roznyatovsky V.A., Tafeenko V.A., Abo Qoura L., Pokrovsky V.S., Yarovaya O.I., Belyaevskaya S.V., Volobueva A.S., et al. 1,3-Dipolar Cycloaddition of Nitrile Oxides and Nitrilimines to (−)-β-Caryophyllene: Stereoselective Synthesis of Polycyclic Derivatives and Their Biological Testing. Int. J. Mol. Sci. 2024;25:11435. doi: 10.3390/ijms252111435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Raj A.A., Raghunathan R., SrideviKumari M., Raman N. Synthesis, Antimicrobial and Antifungal Activity of a New Class of Spiro Pyrrolidines. Bioorg. Med. Chem. 2003;11:407–419. doi: 10.1016/S0968-0896(02)00439-X. [DOI] [PubMed] [Google Scholar]
  • 45.Otero-Fraga J., Montesinos-Magraner M., Mendoza A. Perspectives on Intermolecular Azomethine Ylide [3+2] Cycloadditions with Non-Electrophilic Olefins. Synthesis. 2016;49:802–809. doi: 10.1055/s-0036-1588662. [DOI] [Google Scholar]
  • 46.Pascual-Escudero A., de Cózar A., Cossío F.P., Adrio J., Carretero J.C. Alkenyl Arenes as Dipolarophiles in Catalytic Asymmetric 1,3-Dipolar Cycloaddition Reactions of Azomethine Ylides. Angew. Chem. Int. Ed. 2016;55:15334–15338. doi: 10.1002/anie.201609187. [DOI] [PubMed] [Google Scholar]
  • 47.Meyer A., Ryan J. 1,3-Dipolar Cycloaddition Reactions of Azomethine Ylides with Carbonyl Dipolarophiles Yielding Oxazolidine Derivatives. Molecules. 2016;21:935. doi: 10.3390/molecules21080935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Doraghi F., Ghanbarlou M., Mahdavian A.M., Bari B., Larijani B., Mahdavi M. Coumarin-3-Carboxylic Acid: C3/C4-Functionalizations and Cyclization Reactions. J. Chem. Sci. 2024;136:42. doi: 10.1007/s12039-024-02267-5. [DOI] [Google Scholar]
  • 49.Thadem N., Rajesh M., Das S. Activator Free Diastereoselective 1,3-Dipolar Cycloaddition: A Quick Access to Coumarin Based Spiro Multi Heterocyclic Adducts. RSC Adv. 2021;11:29934–29938. doi: 10.1039/d1ra05070b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Liu X.-W., Chang S.-Q., Wang Q.-L., Chen S., Wang J.-X., Zhou W., Zhou Y. Decarboxylative-Mediated Regioselective 1,3-Dipolar Cycloaddition for Diversity-Oriented Synthesis of Structurally Exo′-Selective Spiro[Oxindole-Pyrrolidine-Dihydrocoumarin] Hybrids. Synthesis. 2020;52:3018–3028. doi: 10.1055/s-0040-1707895. [DOI] [Google Scholar]
  • 51.Rajeswari M., Kumari S., Khurana J.M. One-Pot Four Component Domino Strategy for the Synthesis of Novel Spirooxindole Pyrrolizine Linked 1,2,3-Triazoles via Stereo- and Regioselective [3 + 2] Cycloaddition Reaction in Acidic Medium. RSC Adv. 2016;6:9297–9303. doi: 10.1039/C5RA26093K. [DOI] [Google Scholar]
  • 52.Trifonov A.V., Gazizov A.S., Tapalova A.S., Kibardina L.K., Appazov N.O., Voloshina A.D., Sapunova A.S., Luybina A.P., Abyzbekova G.M., Dobrynin A.B., et al. Synthesis and Anticancer Evaluation of Novel 7-Aza-Coumarine-3-Carboxamides. Int. J. Mol. Sci. 2023;24:9927. doi: 10.3390/ijms24129927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Alimohammadi K., Sarrafi Y., Tajbakhsh M., Yeganegi S., Hamzehloueian M. An Experimental and Theoretical Investigation of the Regio- and Stereoselectivity of the Polar [3+2] Cycloaddition of Azomethine Ylides to Nitrostyrenes. Tetrahedron. 2011;67:1589–1597. doi: 10.1016/j.tet.2010.12.034. [DOI] [Google Scholar]
  • 54.Basu S., Rana S., Saha P., Ghosh P., Mukhopadhyay C. FeCl3-Catalyzed Synthesis of 6-Thioxo-Hexahydroindeno[1′,2′:4,5]Imidazo[1,5-a]Pyridin-12(6H)-ones via an Interesting [1,2] Oxygen Shift Pathway. J. Org. Chem. 2022;87:9755–9763. doi: 10.1021/acs.joc.2c00788. [DOI] [PubMed] [Google Scholar]
  • 55.Nagy P.I., Takács-Novák K. Theoretical and Experimental Studies of the Zwitterion ⇌ Neutral Form Equilibrium of Ampholytes in Pure Solvents and Mixtures. J. Am. Chem. Soc. 1997;119:4999–5006. doi: 10.1021/ja963512f. [DOI] [Google Scholar]
  • 56.Nagy P.I., Alagona G., Ghio C. Theoretical Investigation of Tautomeric Equilibria for Isonicotinic Acid, 4-Pyridone, and Acetylacetone in Vacuo and in Solution. J. Chem. Theory Comput. 2007;3:1249–1266. doi: 10.1021/ct6002252. [DOI] [PubMed] [Google Scholar]
  • 57.Schwarz A., Uray G., Junek H. Notiz Über Die Reaktion von Carbonsäurehalogeniden Mit Ninhydrin. Liebigs Ann. Chem. 1980;11:1919–1922. doi: 10.1002/jlac.198019801131. [DOI] [Google Scholar]
  • 58.Kaupp G., Naimi-Jamal M.R., Schmeyers J. Quantitative Reaction Cascades of Ninhydrin in the Solid State. Chem. A Eur. J. 2002;8:594–600. doi: 10.1002/1521-3765(20020201)8:3<594::AID-CHEM594>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  • 59.Natarajan P., Chaudhary R., Venugopalan P. Ipso-Nitration of Carboxylic Acids Using a Mixture of Nitronium Tetrafluoroborate, Base and 1-Hexyl-3,4,5-Trimethyl-1H-Imidazolium Tetrafluoroborate. Tetrahedron Lett. 2019;60:1720–1723. doi: 10.1016/j.tetlet.2019.05.057. [DOI] [Google Scholar]
  • 60.Natarajan P., Chaudhary R., Venugopalan P. Silver(I)-Promoted Ipso-Nitration of Carboxylic Acids by Nitronium Tetrafluoroborate. J. Org. Chem. 2015;80:10498–10504. doi: 10.1021/acs.joc.5b02133. [DOI] [PubMed] [Google Scholar]
  • 61.Goossen L.J., Rodríguez N., Linder C. Decarboxylative Biaryl Synthesis from Aromatic Carboxylates and Aryl Triflates. J. Am. Chem. Soc. 2008;130:15248–15249. doi: 10.1021/ja8050926. [DOI] [PubMed] [Google Scholar]
  • 62.Xue L., Su W., Lin Z. Mechanism of Silver- and Copper-Catalyzed Decarboxylation Reactions of Aryl Carboxylic Acids. Dalton Trans. 2011;40:11926–11936. doi: 10.1039/c1dt10771b. [DOI] [PubMed] [Google Scholar]
  • 63.Gomes G.d.P., Wimmer A., Smith J.M., König B., Alabugin I.V. CO2 or SO2: Should It Stay, or Should It Go? J. Org. Chem. 2019;84:6232–6243. doi: 10.1021/acs.joc.9b00503. [DOI] [PubMed] [Google Scholar]
  • 64.Sigalov M.V. Keto–Enol Tautomerism of Phenindione and Its Derivatives: An NMR and Density Functional Theory (DFT) Reinvestigation. J. Phys. Chem. A. 2015;119:1404–1414. doi: 10.1021/jp512461c. [DOI] [PubMed] [Google Scholar]
  • 65.Sigalov M., Lemcoff N.G., Shainyan B., Chipanina N., Aksamentova T. Enol Forms of 1,3-Indanedione, Their Stabilization by Strong Hydrogen Bonding, and Zwitterion-Assisted Interconversion. Eur. J. Org. Chem. 2010;2010:2800–2811. doi: 10.1002/ejoc.201000026. [DOI] [Google Scholar]
  • 66.Trifonov A.V., Appazov N.O., Bagautdinova R.K., Kibardina L.K., Pudovik M.A., Lyubina A.P., Voloshina A.D., Gazizov A.S., Tolegen A.E., Togyzbayeva N.A., et al. New Derivatives of Coumarin-3-Carboxylic Acid Containing a Furopyridine Fragment: Synthesis and Some Properties. Russ. J. Gen. Chem. 2025;95:2192–2199. doi: 10.1134/S1070363225603369. [DOI] [Google Scholar]
  • 67.Krause L., Herbst-Irmer R., Sheldrick G.M., Stalke D. Comparison of Silver And Molybdenum Microfocus X-Ray Sources For Single-Crystal Structure Determination. J. Appl. Crystallogr. 2015;48:3–10. doi: 10.1107/S1600576714022985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Dolomanov O.V., Bourhis L.J., Gildea R.J., Howard J.A.K., Puschmann H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Cryst. 2009;42:339341. doi: 10.1107/S0021889808042726. [DOI] [Google Scholar]
  • 69.Sheldrick G.M. SHELXT—Integrated Space-Group and Crystal-Structure Determination. Acta Crystallogr. Sect. A Found. Adv. 2015;71:3–8. doi: 10.1107/S2053273314026370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Sheldrick G.M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. Sect. C Struct. Chem. 2015;71:3–8. doi: 10.1107/S2053229614024218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Macrae C.F., Sovago I., Cottrell S.J., Galek P.T.A., McCabe P., Pidcock E., Platings M., Shields G.P., Stevens J.S., Towler M., et al. Mercury 4.0: From Visualization to Analysis, Design and Prediction. J. Appl. Crystallogr. 2020;53:226–235. doi: 10.1107/S1600576719014092. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ijms-27-09600-s001.zip (5.7MB, zip)

Data Availability Statement

The data presented in this study are contained within the article or in Supplementary Materials or are available upon request from the corresponding author Alexey V. Trifonov.


Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES